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Abstract 
Gene mutation and genomic abnormality are the characteristics of cancer leading to 
aberrant cell growth. Tumors accumulate abnormalities during their somatic evolution 
of life and acquire intra-tumor heterogeneity. When malignant cells obtain a driver 
mutation or genetic alteration on oncogene or tumor suppressor gene, their feature 
becomes more aggressive and dominant in tumor tissues. In the studies described here, 
I focused on a fusion kinase of echinoderm microtubule associated protein like 4 (EML4) 
and anaplastic lymphoma receptor tyrosine kinase (ALK), EML4-ALK, and further Fms-
like tyrosine kinase 3 (FLT3) with constitutively active mutation, which are driver 
mutations in a subset of non-small cell lung cancer (NSCLC) and acute myeloid 
leukemia (AML), respectively. For both tumor types, their kinase inhibitors, ASP3026 
and gilteritinib were investigated to elucidate their basic profiles as anticancer drug 
candidates prior to initiation of each clinical trial. In addition, revealing the roles of both 
aberrant kinases in cancer biology was also aimed for the studies. 
In the first part, ASP3026 was characterized in NSCLC cells with EML4-ALK. 
ASP3026 inhibited ALK activity in an ATP-competitive manner. In mice xenografted 
with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well 
absorbed in tumor tissues, reaching concentrations >10-fold higher than those in plasma, 
and induced tumor regression with a wide therapeutic margin between efficacious and 
toxic doses. ASP3026 also showed potent antitumor activities, including tumor 
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shrinkage to a non-detectable level, in hEML4-ALK transgenic mice and prolonged 
survival in mice with intrapleural NCI-H2228 xenografts. In an intra-hepatic xenograft 
model using NCI-H2228 cells, ASP3026 induced continuous tumor regression, whereas 
mice treated with crizotinib showed tumor relapse after an initial response. Finally, 
ASP3026 exhibited potent antitumor activity against cells expressing EML4-ALK with 
a mutation in the gatekeeper position (L1196M) that confers crizotinib resistance. Taken 
together, these findings indicate that ASP3026 has potential efficacy for NSCLC and is 
expected to improve the therapeutic outcomes of cancer patients with ALK abnormality. 
In the second part, gilteritinib was characterized in AML cells with FLT3 active 
mutation. Initial kinase studies showed that gilteritinib, a type I tyrosine kinase inhibitor, 
was highly selective for both FLT3 and AXL while having weak activity against c-KIT. 
Gilteritinib demonstrated potent inhibitory activity against the internal tandem 
duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays using MV4-
11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib also 
inhibited FLT3-F691 mutations, although to a lesser degree, in these assays. Furthermore, 
gilteritinib decreased the phosphorylation levels of FLT3 and its downstream targets in 
both cellular and animal models. In vivo, gilteritinib was distributed at high levels in 
xenografted tumors after oral administration. The decreased FLT3 activity and high 
intratumor distribution of gilteritinib translated to tumor regression and improved 
survival in xenograft and intra-bone marrow transplantation models of FLT3-driven 
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AML. No overt toxicity was seen in mouse models treated with gilteritinib. These results 
indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in 
the treatment of FLT3 mutation-positive AML. 
In the pharmacology studies with ASP3026, it selectively inhibited ALK activity and 
showed an antitumor efficacy against tumor cells harboring EML4-ALK. ASP3026 also 
showed its efficacy against cells resistant to another ALK inhibitor. In the studies with 
gilteritinib, it selectively inhibited FLT3 sparing c-KIT and prolonged survival in an 
animal model with AML cells harboring of active mutation of FLT3. From these results, 
I revealed the attractive pharmacology profiles of both compounds that they showed 
antitumor activity in several models including resistant models to another compound 
through inhibiting target molecules. 
These study results also indicated the dependencies of ALK and FLT3-mutated cells on 
each driver kinase for their growth and survival. As the sensitivities (inhibitory activities) 
of each inhibitor differ among cells and animal models tested, it was inferred that several 
other intra- and extra-cellular factors than driver kinases are also involved in 
maintenance of tumors. The outcomes of clinical trials for both compounds have been 
already available. While they showed efficacies in NSCLC and AML patients with driver 
mutated kinases as expected, the diseases have made progresses with time in many 
patients. Tumors are not uniform aberrant cells but consist of heterogeneous tumor cells. 
There are possibilities that minor tumor cells, which are not dependent on driver kinases, 
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emerged to be prominent, targeted cells acquired additional mutations on the kinases not 
to be effective to the therapies and/or other alternative signal pathways were activated. 
In the series of experiments, I partly revealed the roles of both driver kinases in tumors, 
which would lead to further understanding of cancer biology toward concurring cancer. 
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Abbreviations 
 
ALK  anaplastic lymphoma ceceptor tyrosine kinase 
AML  acute myeloid leukemia 
ATCC  American Type Culture Collection 
AUC  area under the plasma concentration–time curve 
BLI  bioluminescent imaging 
Cmax   maximum plasma concentration 
CML  chronic myeloid leukemia 
CT  computed tomography 
EGFR  epidermal growth factor receptor 
EML4  echinoderm microtubule associated protein like 4 
FLT3  fms-like tyrosine kinase 3 
IBMT  intra-bone marrow transplantation 
IC50  half maximal inhibitory concentration 
ITD  internal tandem duplication 
KIF5B  kinesin family member 5B 
MSA  mobility shift assay 
NSCLC  non-small cell lung cancer 
PD-1  programmed cell death 1 
PDB  Protein Data Bank 
TBS-T  tris buffered saline tween-20 
TFG  tropomyosin receptor kinase (TRK)-fused gene 
TK  tyrosine kinase 
TKI  tyrosine kinase inhibitor 
TKD  tyrosine kinase domain 
Tmax  time to reach maximum plasma concentration 
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General Introduction 
Cancer is one of the major causes of mortality in the world. In Japan, more than 300,000 
people die of cancer in a year, which accounts for around 30% of all cases according to 
the Vital Statistics issued by Ministry of Health, Labour and Welfare in 2016 (1). What 
are the differences between normal cells and malignant cells? One of the characteristics 
of cancer is aberrant cell growth resulting from gene mutation and/or genomic 
abnormality (2-4). Malignant cells suppress gene repair of aberrant genes and further 
survive without falling into apoptosis (5). Malignant cells also acquire the ability to 
escape from immune surveillance (6). Malignant cells sometimes have the potential to 
metastasize to another region in the same organ and another tissue. When malignant cells 
disturb the functions of normal tissues, the life of the patient would be threatened, 
regardless of whether the malignant cells grow in the original place or metastasized 
places. As such, a variety of aberrances is responsible for each type of cancers as well as 
each tumor cell. 
Gene mutation or genetic alteration is the initial step for cancer development. Tumors 
accumulate abnormalities during their somatic evolution of life and acquire intra-tumor 
heterogeneity (7). When malignant cells obtain a driver mutation or genetic alteration on 
oncogene or tumor suppressor, their feature becomes more aggressive and dominant in 
tumor tissues. Other passenger mutations they probably have would further contribute to 
support the tumor development of dominant malignant cells. 
 7 
 
There are many evidences showing that a cancer driver mutation or genetic alteration 
is a key to tumor development for certain types of cancers. For example, the driver 
tyrosine kinase BCR-ABL, which is a fusion protein of BCR and ABL, is implicated in 
the pathogenesis of chronic myeloid leukemia (CML), and imatinib, an inhibitor of BCR-
ABL, induces hematological and cytogenetic responses that help prevent disease 
progression (8, 9). In CML, the Philadelphia chromosome as a hallmark is resulting from 
a reciprocal translocation between the long arms of chromosomes 9 and 22. The resulting 
fusion protein, BCR-ABL, is constitutively active tyrosine kinase that can transform 
myeloid progenitor cells and drives the development of CML. Cancer drivers, which 
could be molecular targets of therapies, are also found in solid malignancies and the 
targeted therapies have proved effective against them, such as the use of trastuzumab 
against HER2 in breast cancer (10), gefitinib and erlotinib against epidermal growth 
factor receptor (EGFR) in NSCLC (11-13), and vemurafenib against BRAF V600E in 
melanoma (14). In the EGFR and BRAF cases, a point mutation of each receptor makes 
the tyrosine kinase to be constitutively active and promotes the development of tumors. 
These mutated receptors become oncogenes. In the HER2 case, its overexpression or 
amplification contributes to the dependency of the tumor cells to the growth signal. 
Regarding research and development of cancer drugs, kinase inhibitors are attractive 
therapeutics against cancer with specific driver mutations (15). The targets are druggable 
and the high efficacies are expected due to their dependency on the kinase activities for 
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the growth and survival. In addition, the inhibitors would be strong tools for 
understanding cancer biology. Firstly, in the discovery stage of drugs, it should be 
investigated whether the inhibitors can inhibit the cancer cell growth and induce cell 
death in vitro. It is also important to confirm the inhibition of target kinase and the 
downstream signal transduction in target cells. The inhibitors should be well absorbed, 
if oral application is desired, and be importantly well tolerated in animals. From a set of 
experiments using cell lines with driver mutations, one can know whether the inhibitors 
have a potential to be effective against cancers with the target mutations and confirm the 
dependency of the cells on the mutations at least in the non-clinical conditions. 
Cancer biology in real patients would be more complex and the situation of tumor cells 
would differ by patients and even among tumors in the same patient (7). In addition to 
diversity of malignant cells in their abnormalities, their microenvironments such as 
growth environment, oxygen/energy conditions, and interaction with stromal cells, also 
differ among cells which causes cancer biology to be further complex. In the case of 
CML, most patients well responded to the ABL inhibitors and the efficacies lasted for a 
long time (9). The patients can even expect to become cured. The complexity and 
heterogeneity of CML is thought to be lower compared to solid tumors, where the 
efficacy is usually partial and tentative and the relapse will happen roughly 10 to 12 
months after the tumor shrinkage in median (10-14, 16-18). In the case of relapse, tumor 
cells usually have additional mutations to evade the inhibitors’ efficacy. The mutations 
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are often found in another position of the kinase for which the inhibitor shows weaker 
activity and/or in another kinase which can activate the downstream of the original target 
kinase. In other cases, another clone could be dominant instead of the original clone. 
Cancer dynamically evolves in its biological properties also with the treatment. 
In the studies described in this dissertation, I revealed the basic profiles of ALK 
inhibitor ASP3026 against ALK-mutated NSCLC and FLT3/AXL inhibitor gilteritinib 
against FLT3-mutated acute myeloid leukemia in non-clinical settings to elucidate their 
potentials as anticancer drug candidates prior to initiation of each clinical trial. I also 
confirmed the driver kinase dependencies of tumor cells in a set of experiments in vitro 
and in vivo with aiming to reveal the roles of both aberrant kinases in cancer biology. 
These inhibitors could be useful tools to elucidate cancer biology through non-clinical, 
clinical, and the mixed approaches in future. 
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Part I 
 
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces 
tumor regression and prolongs survival in non-small cell lung cancer model mice 
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Abstract 
Activation of anaplastic lymphoma receptor tyrosine kinase (ALK) is involved in the 
pathogenesis of several carcinomas, including non-small cell lung cancer (NSCLC). 
Echinoderm microtubule associated protein like 4 (EML4)-ALK, which is derived from 
the rearrangement of ALK and EML4 genes, has been validated as a therapeutic target in 
a subset of NSCLC patients. Here, my colleagues and I investigated the effects of 
ASP3026, a novel small molecule ALK inhibitor, against ALK-driven NSCLC. 
ASP3026 inhibited ALK activity in an ATP-competitive manner and had an inhibitory 
spectrum that differed from that of crizotinib, a dual ALK/MET inhibitor. In mice 
xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered 
ASP3026 was well absorbed in tumor tissues, reaching concentrations >10-fold higher 
than those in plasma, and induced tumor regression with a wide therapeutic margin 
between efficacious and toxic doses. In the same mouse model, ASP3026 enhanced the 
antitumor activities of paclitaxel and pemetrexed without affecting body weight. 
ASP3026 also showed potent antitumor activities, including tumor shrinkage to a non-
detectable level, in hEML4-ALK transgenic mice and prolonged survival in mice with 
intrapleural NCI-H2228 xenografts. In an intra-hepatic xenograft model using NCI-
H2228 cells, ASP3026 induced continuous tumor regression, whereas mice treated with 
crizotinib showed tumor relapse after an initial response. Finally, ASP3026 exhibited 
potent antitumor activity against cells expressing EML4-ALK with a mutation in the 
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gatekeeper position (L1196M) that confers crizotinib resistance. Taken together, these 
findings indicate that ASP3026 has potential efficacy for NSCLC and is expected to 
improve the therapeutic outcomes of cancer patients with ALK abnormality. 
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Introduction 
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer 
death worldwide (19). Treatment outcomes with conventional antitumor drugs in 
advanced or metastatic non-small-cell lung cancer (NSCLC) remain unsatisfactory due 
to low rates of response and long-term survival (20). However, in the last few decades, 
investigations of the molecular mechanisms of cancer pathogenesis have identified 
several cancer drivers, such as receptor tyrosine kinases (TKs), which have been used 
for new, targeted therapies against several types of cancers, including NSCLC (8-13). 
Such therapies have markedly improved response rates and survival outcomes of cancer 
patients, and represent a paradigm shift in cancer treatment. For example, the driver TK 
BCR-ABL is implicated in the pathogenesis of chronic myeloid leukemia, and imatinib, 
an inhibitor of BCR-ABL, induces hematological and cytogenetic responses that help 
prevent disease progression (8, 9). Targeted therapies against cancer drivers have also 
proved effective against solid malignancies, such as the use of trastuzumab against HER2 
in breast cancer (10), gefitinib and erlotinib against epidermal growth factor receptor 
(EGFR) in NSCLC (11-13), and vemurafenib against BRAF V600E in melanoma (14). 
EML4-ALK is a fusion gene comprising portions of the echinoderm microtubule 
associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK) genes, and was 
first found in a subset of NSCLC cells (21, 22). Soda and colleagues (21) discovered 
EML4-ALK by screening a retroviral complementary DNA expression library generated 
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from a lung adenocarcinoma specimen surgically resected from a 62-yr-old man with a 
smoking history. EML4-ALK was formed through disruption of EML4 at a position ∼3.6-
kb downstream of exon 13 and ligation to a position 297-bp upstream of exon 21 of ALK. 
EML4–ALK has transforming potential that is dependent on its kinase activity, while the 
coiled-coil domain of EML4 mediates the constitutive dimerization and cytoplasmic 
activation of EML4-ALK, which together are responsible for the generation of 
transformed cell foci in vitro and tumor formation in nude mice (21). Separately, Rikova 
and colleagues (22) discovered a variant of EML4-ALK, in which intron 6 of EML4 is 
fused to the ALK gene, and another ALK fusion protein, TRK-fused gene (TFG)-ALK, 
during phosphoproteomic analyses of tyrosine signaling. More recently, Takeuchi and 
colleagues (23) identified a novel oncokinase fusion protein, kinesin family member 5B 
(KIF5B)-ALK, using an immunohistochemistry-based diagnostic system. The 
identification of these various ALK-fusion proteins indicates that the kinase activity of 
ALK plays an important role in the pathogenesis of a subset of NSCLC. In addition, 
treatment of spontaneous pulmonary tumor in hEML4-ALK transgenic mice with an ALK 
inhibitor or repression of ALK expression results in tumor regression (24, 25). Together, 
these experimental evidences suggest that EML4-ALK is a targetable genetic lesion in 
NSCLC (26). 
ALKoma, tumors carrying abnormal ALK as an essential growth driver, have also 
been found in several cancer types other than NSCLC (27). In these tumor cells, ALK is 
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rendered oncogenic as a result of its fusion to various proteins, including nucleophosmin 
(nucleolar phosphoprotein B23, numatrin) in anaplastic large cell lymphoma (28), 
tropomyosin 3 or 4 in inflammatory myofibroblastic tumors (29), vinculin in renal 
medullary carcinoma (30, 31), and clathrin in ALK-positive diffuse large B-cell 
lymphoma (32). In addition, activated mutation of ALK is also involved in the 
development of neuroblastoma and anaplastic thyroid cancer (33, 34). Several ALK 
inhibitors with efficacy against ALKoma in preclinical models and patients have been 
identified (35-38). For example, the small-molecule ALK and MET inhibitor crizotinib 
exhibited high efficacy with overall response rates of ≥50% in clinical trials of NSCLC 
patients harboring an EML4-ALK oncogenic kinase (16, 17). However, the treatment 
was not curative, and the patients developed resistance in target lesions and/or metastatic 
sites and had a progression free survival of only approximately 10 months (16-18). Two 
secondary point mutations (L1196M and C1156Y) have been identified within the kinase 
domain of EML4-ALK in tumor cells isolated from a patient who relapsed after an initial 
response to crizotinib (39). The point mutation L1196M is analogous to other kinase 
domain mutations, including the T790M mutation in EGFR (40) and T315I mutation in 
BCR-ABL (41), in gatekeeper positions seen in patients who developed resistance to 
tyrosine kinase inhibitor (TKI) treatment (41). The gatekeeper position including the 
L1196M mutation site is located at the bottom of the ATP-binding pocket of EML4-ALK, 
and the presence of an amino acid with a bulky side chain at this position interferes with 
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the interaction of the TKI with the kinase domain of the target protein, thereby decreasing 
the efficacy of treatment (42). Thus, more potent ALK inhibitors, such as those capable 
of inhibiting L1196M ALK, are needed to overcome the resistance that often develops 
in both lung and metastatic sites. 
In the present study, my colleagues and I characterized a recently discovered novel 
and selective small molecule ALK inhibitor, ASP3026, against ALK-driven NSCLC 
tumors in a non-clinical setting to elucidate the potential as an anticancer drug candidate 
prior to initiation of the clinical trial and also to reveal the role of the aberrant kinase in 
cancer biology. My colleagues and I examined the inhibitory effects of ASP3026 against 
ALK in cell-free systems and cellular assays, and evaluated the antitumor activity and 
survival benefits of ASP3026 in mouse models with ALK-driven tumors in lung and 
metastatic sites. In addition, my colleagues and I also evaluated the antitumor activity of 
ASP3026 against cells expressing EML4-ALK with a mutation in the gatekeeper 
position and in combination with conventional antitumor agents in mouse models of 
NSCLC. 
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Materials and Methods 
Compounds, cell lines, and antibodies 
ASP3026 (43) and crizotinib were synthesized by Astellas Pharma Inc. (Tokyo, Japan). 
Paclitaxel and pemetrexed were purchased from LC laboratories (Woburn, MA, USA), 
and carboplatin was obtained from Bristol-Myers Squibb (New York, NY, USA). NCI-
H2228 cells were purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) in July 2007 and authenticated by Short Tandem Repeat profiling 
(Cell ID, Promega). H2228-luc cells, which exogenously express firefly luciferase, were 
prepared at Astellas Pharma Inc. 3T3 cells were obtained from the ATCC in June 2007 
(not authenticated) and were engineered to express either wild-type (EML4-ALK/3T3) 
or L1196M-mutated EML4-ALK (L1196M/3T3). Antibodies to ALK (C26G7), 
phosphorylated ALK (Tyr1604), p44/42 MAPK (Erk1/2), Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (197G2), Phospho-Stat3 (Tyr705), Akt, and Phospho-Akt 
(Ser473) (193H12) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, 
USA). Anti-actin antibody A2066 was purchased from Sigma-Aldrich Co. (St. Louis, 
MO, USA). 
Kinase inhibitory assays 
EML4-ALK variant 1 kinase and its L1196M-mutated form were isolated from Ba/F3 
cells transformed with the respective forms of EML4-ALK. Kinase activity was 
measured with HTRF® KinEASE™-TK (SCETI Medical Labo K.K., Tokyo, Japan) in 
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the presence of various concentrations of ASP3026 or crizotinib. 
An inhibitory assay for a panel of 86 TKs (Table 1) was conducted using ATP 
concentrations that were approximately equal to the Km value for each kinase using a 
TK-ELISA or Off-chip Mobility Shift Assay (MSA) at Carna Biosciences, Inc. (Kobe, 
Japan). The inhibitory percentage of ASP3026 and crizotinib against kinase activity was 
first determined at concentrations of 100 and 1000 nM in a single experiment. Half 
maximal inhibitory concentration (IC50) values were then separately determined in the 
presence of various concentrations of each compound in three individual experiments. 
Anti-proliferative assays 
NCI-H2228 cells were plated in RPMI 1640 supplemented with 10% heat-inactivated 
FBS in 96-well Sumilon cell-tight spheroid plates (Sumitomo Bakelite, Tokyo, Japan) at 
2000 cells/well and then incubated at 37°C in a 5% CO2 atmosphere overnight. The cells 
were exposed to test compounds, which were dissolved in DMSO as a solvent, for 5 days, 
and viable cell numbers were then determined using the CellTiter-GloTM Luminescent 
Cell Viability Assay (Promega, Madison, WI, USA). The IC50 value of each compound 
was calculated by nonlinear regression analysis using the Sigmoid-Emax model, and the 
mean IC50 values were calculated from four individual experiments. In the assay with 
3T3 cells, the cells were plated in DMEM supplemented with 10% heat-inactivated FBS 
in 96-well spheroid plates (Sumitomo Bakelite) at 500 cells/well, incubated overnight, 
and then treated with the test compounds for 2 days. The IC50 values were determined 
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from a single experiment.  
Immunoblotting 
NCI-H2228 cells were seeded at 4 to 5×105 cells/well in 12-well HydroCellTM plates 
(CellSeed, Tokyo, Japan), incubated for 2 days, and ASP3026 was then added to each 
well at a final concentration of 0 (DMSO), 10, 100, or 1000 nM. Cell lysates were 
prepared for immunoblot analysis of EML4-ALK, ERK, STAT3, AKT, and actin after 4 
h of ASP3026 treatment. In an in-vivo experiment, mice with NCI-H2228 tumors were 
treated with ASP3026 at a single oral dose of 10 mg/kg, and tumors were then excised 4 
h after administration.  
The lysates from cell and tumor samples were separated by electrophoresis and then 
transferred onto nitrocellulose membranes. After blocking with Blocking One or 
Blocking One-P (Nacalai Tesque, Kyoto, Japan) for 1 h, each membrane was incubated 
with anti-ALK, anti-phospho-ALK, anti-ERK, anti-phospho-ERK, anti-phospho-STAT3, 
anti-AKT, or anti-phospho-AKT antibodies overnight at 4°C. The membranes were 
washed with 1×tris buffered saline tween-20 (TBS-T, Thermo Fisher Scientific Inc., 
Rockford, IL, USA) and then incubated with anti-rabbit IgG HRP-linked antibody (Cell 
Signaling Technology) for 1 h at room temperature. After a final washing, ECL Western 
Blotting Detection Reagents (GE Healthcare, Chalfont St. Giles, UK) were applied to 
the membranes, and signals were detected with a CCD camera (AISIN, Aichi, Japan) 
and quantified using a LumiVision PRO 400EX system (Taitec, Saitama, Japan) or 
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ImageJ software (NIH, Bethesda, MD, USA). The mean percentage of phosphorylated 
protein/total protein relative to that in vehicle-treated cells was then calculated.  
In-vivo models 
All animal experimental procedures were approved by the Institutional Animal Care 
and Use Committee of Astellas Pharma Inc. Furthermore, Astellas Pharma Inc., Tsukuba 
Research Center was awarded Accreditation Status by AAALAC International. ASP3026 
and crizotinib in a 0.5% methylcellulose solution were administered orally at once or 
twice daily doses starting after confirming tumor growth in each experiment. NCI-H2228 
cells were subcutaneously inoculated into the flank of male NOD-SCID mice 
(NOD.CB17-Prkdcscid/J, Charles River Laboratories Japan, Inc., Kanagawa, Japan) at 
5×106 cells/0.1 mL/mouse. EML4-ALK/3T3 and EML4-ALK L196M/3T3 cells were 
subcutaneously inoculated into the flank of the male nude mice (CAnN.Cg-
Foxn1nu/CrlCrlj[nu/nu], Charles River Laboratories Japan, Inc.) at 3×106 cells/0.1 
mL/mouse. Tumor diameter was measured using a caliper and tumor volume was 
determined by calculating the volume of an ellipsoid using the formula: length × width2 
× 0.5. 
In an intrapleural xenograft model, H2228-luc cells were directly inoculated at 1×105 
cells/20 μL/mouse into the pleural cavity of male NOD/SCID mice under anesthesia with 
isoflurane. In an intra-hepatic xenograft model, H2228-luc cells were directly inoculated 
into the portal vein of male NOD/SCID mice at 1×106 cells/100 μL/mouse. Tumor 
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growth was monitored by bioluminescent imaging (BLI) of the chest and abdominal 
areas with an IVIS Spectrum Imaging System (Caliper Life Sciences, Hopkinton, MA). 
The survival of mice was monitored daily. 
hEML4-ALK transgenic mice were provided by Jichi Medical University (Tochigi, 
Japan) and were generated as previously described (24). Briefly, a complementary DNA 
fragment encoding EML4-ALK variant 1 was ligated to the surfactant protein C 
promoter and then injected into pronuclear-stage embryos of C57BL/6J mice. The 
tumors were monitored by computed tomography (CT) scan, which was performed for 
approximately 5 min under anesthesia induced with 2.5% isoflurane using an Inveon CT 
(Siemens, Munich, Germany). Data reconstruction and analysis were performed using 
Inveon Acquisition Workplace software (Siemens). Volumes of interests were manually 
drawn for pulmonary tumors detected in the CT images. 
Pharmacokinetics 
NOD-SCID mice subcutaneously xenografted with NCI-H2228 cells received a 5-day 
repeated oral dosing of 1, 3, and 10 mg/kg ASP3026 suspended in a 0.5% 
methylcellulose solution. Blood samples were collected from the inferior vena cava 
using a heparinized syringe, and plasma samples were prepared by centrifugation. Tumor 
samples were also collected from each mouse, and tumor weight was measured. The 
plasma and tumor concentrations of ASP3026 were measured using high-performance 
liquid chromatography-tandem mass spectrometry at Toray Research Center, Inc. 
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(Kanagawa, Japan). Maximum plasma concentration (Cmax), time to reach maximum 
plasma concentration (Tmax), and area under the plasma concentration–time curve from 
time 0 h to 24 h (AUC0-24h) were calculated from the mean concentrations of ASP3026 
using WinNonlin Professional V6.1 (Pharsight, Mountain View, CA, USA). 
Computational modeling 
As the X-ray structures of both wild-type ALK and the L1196M variant of ALK with 
crizotinib (PDB ID: 2XP2 and 2YFX) are publicly available, computation models of 
crizotinib were generated by adding missing hydrogen atoms and minimizing the 
coordinates of hydrogen atoms using MOE (Chemical Computing Group Inc., Montreal, 
Quebec, Canada). Docking simulation of ASP3026 with wild-type ALK was performed 
using the docking software GLIDE (Schrodinger, LLC, New York, NY, USA). Wild-type 
ALK with NVP-TAE684 (PDB ID: 2XB7) was used as a template for the docking, and 
hydrogen atoms were added using MOE. The docking mode with the highest docking 
score was employed in the modeling. The binding model of ASP3026 and ALK L1196M 
was generated by superimposing the backbone atoms of the protein coordinates over 
those of the 2YFX structure. All of the figures showing X-ray structures and docking 
results were constructed using MOE. 
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Results 
ASP3026 inhibits the growth of ALK-dependent cells 
ASP3026 was identified through a medicinal chemistry campaign (Fig. 1A) designed 
to obtain compounds with different profiles from a reported ALK inhibitor (43, 44). The 
kinase selectivity of ASP3026 was evaluated and compared with that of crizotinib 
against a panel of 86 TKs (Table 1). ASP3026 inhibited 11 TKs by more than 50% at 
1000 nM, and had the highest selectivity for ALK, ROS, and ACK kinases (Table 2). The 
kinase selectivity of ASP3026 clearly differed from that of crizotinib. Specifically, 
ASP3026 was more selective for FRK, YES, ACK, TNK1, and EGFR (L858R) among 
all tested kinases, whereas crizotinib had higher selectivity for MET, RON, LCK, JAK2, 
MUSK, TRKs, TYRO3, AXL, MER, and EPHs. 
My colleagues and I next evaluated the anti-proliferative activity of ASP3026 against 
NCI-H2228 NSCLC cells endogenously expressing EML4-ALK variant 3 using a 
spheroid cell culture system. After 5 days of treatment, ASP3026 inhibited the growth of 
NCI-H2228 cells with an IC50 value of 64.8 nM (Fig. 1B). This value was higher than 
the concentration of ASP3026 required to achieve comparable results in the kinase 
inhibitory assays, and may possibly have been due to a higher ATP concentration in the 
NCI-H2228 NSCLC cells than that used in the assay. The growth suppression was 
accompanied by inhibition of ALK phosphorylation in the cells, in which the levels of 
phosphorylated ALK were 70%, 40%, and 9% after 4-h treatment with 10, 100, and 1000 
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nM ASP3026, respectively, compared to the vehicle-treated control cells (Fig. 1C). In 
addition, ASP3026 treatment also resulted in suppression of phosphorylation of AKT, 
ERK, and STAT3 at 100 and 1000 nM (Fig. 1C and Table 3). 
 
ASP3026 induces shrinkage of ALK-dependent NSCLC tumors  
My colleagues and I next evaluated the antitumor activity of ASP3026 in a NCI-
H2228 subcutaneous xenograft mouse model by examining the inhibitory effect of 
ASP3026 on ALK phosphorylation. A significant (approximately 20%; p<0.001) 
decrease in phosphorylated ALK was observed 4 h after a single oral administration of 
10 mg/kg ASP3026 (Fig. 2A). In this model, once-daily oral administration of ASP3026 
at 1, 3, 10 and 30 mg/kg/day for 2 weeks dose-dependently inhibited the growth of NCI-
H2228 tumors by 69%, >100%, >100%, and >100%, respectively, and induced tumor 
regression by 0%, 4%, 45%, and 78%, respectively (Fig. 2B). Body weight was not 
affected by treatment with ASP3026 at any dose, even at 100 mg/kg twice daily (bid) 
(data not shown, Fig. 3).  
Consistent with the observed antitumor activity, ASP3026 was well absorbed after oral 
administration, with higher concentrations detected in tumor tissues than in plasma at 
each time point.  The tumor/plasma ratios were 13 to 19 for Cmax and 19 to 23 for 
AUC0-24h (Fig. 2C and Table 4). 
To further evaluate the antitumor activity of ASP3026, hEML4-ALK transgenic mice 
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were treated with once-daily oral dosing of ASP3026 for 10 days after tumors were 
established in lungs. A series of CT scans taken during the treatment period clearly 
revealed a reduction of the tumor mass, with complete responses detected in 2 of 3 mice 
on day 7, and 3 of 3 mice on day 11 after the initiation of treatment at 100 mg/kg (Fig. 
4). A significant reduction of pulmonary tumor size in mice treated with 30 and 100 
mg/kg ASP3026 was observed, as determined by the quantitative analysis of CT images 
taken on days 7 and 11 (Fig. 2D). The penetration of ASP3026 into tumors of this 
transgenic mouse model was confirmed by measurement of the drug concentration in 
tumors, which was over 100-fold higher compared to those in plasma at approximately 
24 h after the final dosing (2295 and 8005 ng/g in tumors, 23 and 43 ng/mL in plasma at 
10 and 30 mg/kg, respectively). 
 
ASP3026 enhances antitumor activities of paclitaxel and pemetrexed in mice with 
ALK-dependent NSCLC tumors 
The antitumor activity of ASP3026 in combination with several NSCLC drugs was 
investigated in a subcutaneous NCI-H2228 xenograft model. Paclitaxel at 12 mg/kg 
induced tumor regression against NCI-H2228 xenografts, and the combination of 
paclitaxel with ASP3026 at 10 mg/kg caused further significant regression of tumors 
compared with each single-treatment group (Fig. 5A). Body weight loss was observed 
in the paclitaxel treatment groups, but by day 21, body weight had returned to the level 
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at the initiation of treatment and did not significantly differ from control mice. The 
difference of body weight between the combination and paclitaxel single-treatment 
groups did not largely change during the experiment. The combination of ASP3026 at 
10 mg/kg with pemetrexed at 50 mg/kg was also effective at reducing tumor volume, 
which was smaller in the combination group than that in each single-treatment group 
(Fig. 5B). Pemetrexed treatment also induced body weight loss, which was not further 
induced by ASP3026. In contrast to paclitaxel and pemetrexed, ASP3026 did not 
enhance the antitumor activity of carboplatin at 60 mg/kg in this model, as the tumor 
volume of the combination group was similar to that of the ASP3026 single-treatment 
group throughout the experimental period (Fig. 5C). 
 
ASP3026 prolongs survival in mice with intrapleural xenografts of ALK-dependent 
NSCLC cells 
My colleagues and I conducted antitumor assays for xenograft tumors in the pleural 
cavity, which is one of the major metastatic sites for NSCLC. H2228-luc cells were 
directly inoculated into the pleural cavity of mice, and the implanted cells were 
monitored using BLI of the chest area. The bioluminescent emissions of inoculated mice 
showed an approximately 100-fold increase during the 40-day period after cell 
inoculation and disease-related mortality was observed (Fig. 6A and 7). Using this model, 
my colleagues and I also evaluated and compared the efficacy of once-daily oral dosing 
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of ASP3026 and crizotinib. Median survival time was 39 days in vehicle-treated control 
mice and 71 days in crizotinib-treated mice at 30 mg/kg (Fig. 6A). In contrast, no mice 
receiving ASP3026 treatment at 30 mg/kg died during the 90-day experimental period 
(Fig. 6A). The mortality effects were accompanied by changes in the bioluminescent 
emissions, with crizotinib-treated mice at 30 mg/kg showing increased emissions after 
an initial reduction, whereas ASP3026-induced reduction of emissions at 30 mg/kg 
continued throughout the experimental period (Fig. 6B). The mean bioluminescent 
emission in the ASP3026-treated group was significantly lower than that in the 
crizotinib-treated group, indicating that the ASP3026-treated animals exhibited a lower 
tumor burden. 
 
ASP3026 shows antitumor efficacy against ALK-dependent NSCLC tumors in liver 
As the liver is one of the metastatic sites in crizotinib-treated patients with EML4-
ALK positive NSCLC (28), my colleagues and I evaluated the antitumor activity of 
ASP3026 against tumors in the liver. H2228-luc cells were inoculated into the portal vein 
of mice, and the implanted cells were monitored using BLI of the upper abdominal area 
(Fig. 6C). The bioluminescent emissions of inoculated animals decreased during the 
initial 10 days after inoculation and showed an approximately 100-fold increase during 
the subsequent 30 days, with tumors forming in entire lobes of the liver (Fig. 8). During 
the first 10 days of the treatment, crizotinib at 30 mg/kg as a once daily oral dose reduced 
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the BLI signal intensity to one third of that at the initiation of treatment (3.2×108 to 
1.1×108 photons/sec), but the emission increased between days 10 to 20 (1.1×108 to 
2.0×108 photons/sec), which is a similar finding to that observed in the intrapleural 
xenograft model (Fig. 6C). In contrast, the emission was reduced to approximately 1/100 
of that at the initiation of treatment by 30 mg/kg ASP3026 as a once daily oral dose for 
14 days (3.3×108 to 4.2×106 photons/sec), and reached 7.7×105 photons/sec by the end 
of the 19-day experimental period (Fig. 6C). 
 
ASP3026 induces regression of tumors harboring gatekeeper-residue mutation 
L1196M of EML4-ALK 
Mutations in the ALK kinase domain that confer resistance to crizotinib were 
previously identified following sequence analysis of tumor cells derived from a pleural 
effusion of a crizotinib-relapsed patient who experienced disease progression after a 
partial response (31). One of the mutations, L1196M, was observed at a gatekeeper 
position, and it was confirmed that crizotinib shows less inhibitory activity against 
mutated EML4-ALK with L1196M. To assess the inhibitory activity of ASP3026 against 
mutated EML4-ALK, here, in-vitro kinase inhibitory, in-vitro anti-proliferative, and in-
vivo antitumor assays were conducted. ASP3026 inhibited the kinase activities of wild-
type and mutated EML-ALKs with IC50 values of 10 and 32 nM, respectively, whereas 
crizotinib displayed 10-fold weaker activity for mutated EML4-ALK compared to wild 
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type (Table 5A). In the spheroid cell culture system, both compounds concentration-
dependently inhibited the growth of 2-day treated cells, and the IC50 values showed a 
similar tendency to the kinase inhibitory activities. The IC50 ratios of ASP3026 and 
crizotinib against L1196M/3T3 cells versus EML4-ALK/3T3 cells were 3.9 and 9.2, 
respectively (Table 5B). In addition, crizotinib at 100 mg/kg as a once daily oral dose for 
4 days showed no efficacy against L1196M/3T3 tumors, but did induce the regression 
of EML4-ALK/3T3 tumors (Fig. 9A and 9B). In contrast, ASP3026 induced tumor 
regression at 100 mg/kg in both models (Fig. 9A and 9B), indicating the therapeutic 
potential of this drug for patients who are resistant/refractory to crizotinib.  
To further understand and compare the inhibitory activity of ASP3026 and crizotinib 
against mutated EML4-ALK with L1196M, computational modeling of the wild-type 
and L1196M ALK TK domains was performed (Fig. 9C). The modeling revealed that 
wild-type ALK had sufficient space for crizotinib to fit within the ATP-binding pocket, 
whereas the L1196M mutation limits the space available for the methyl group at the 
benzyl position of crizotinib due to the larger side-chain of methionine compared to 
leucine. In contrast, ASP3026 was well docked with both wild-type and L1196M ALK. 
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Discussion 
The discovery of EML4-ALK as a drug-targetable cancer driver led to the 
development of the ALK inhibitor crizotinib, which showed high efficacy in clinical 
trials with NSCLC patients harboring this oncogenic kinase, with overall response rates 
of ≥50% (16, 17). However, the treatment was not curative, and the patients developed 
resistance to crizotinib in brain, liver, and lung tissues with a progression free survival 
of only approximately 10 months (16-18). Therefore, a need exists for the development 
of novel ALK inhibitors and drug combinations to further improve treatment outcomes. 
In the present study, my colleagues and I demonstrated that ASP3026 has growth 
inhibitory activity that is accompanied by a decrease of phosphorylated ALK in NCI-
H2228 ALK-fusion positive NSCLC cells. In mice xenografted with NCI-H2228 cells, 
ASP3026 showed antitumor activity with a wide therapeutic margin between efficacious 
and toxic doses. ASP3026 induced tumor regression at oral doses of 3 mg/kg or more, 
with no apparent toxicity or body weight loss, even at a dose of 100 mg/kg. The broad 
therapeutic margin of ASP3026 is possibly due to its high uptake in tumors, higher ALK 
selectivity, and different spectrum of kinase inhibition compared with crizotinib. In the 
hEML4-ALK transgenic mouse model, ASP3026 also showed potent antitumor activity, 
as assessed by tumor shrinkage in the lung to non-detectable levels in CT scans. Notably, 
however, ASP3026 at 10 mg/kg did not induce tumor regression in this model, possibly 
due to differences in the rate of tumor growth and/or ALK dependency between hEML4-
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ALK transgenic mice and NCI-H2228 xenografted mice. This finding was also supported 
by the higher concentration of orally administered ASP3026 in the lung compared with 
plasma. In a preliminary study of anti-proliferative assays using 145 types of NSCLC-
derived cell lines, only 5 cell lines with ALK fusions, including NCI-H2228 and H3122, 
were sensitive (>50% inhibition at 300 nM) to ASP3026 (data not shown), indicating 
this compound has selective inhibitory activity against ALK-dependent cancer cells. This 
fact might be reflected in the low toxic profile of ASP3026. 
In intrapleural and intra-hepatic xenograft models of NOD/SCID mice with NCI-
H2228 tumors, crizotinib at 30 mg/kg induced tumor regression during the initial 
treatment phase, but tumors then increased in size despite continuation of oral dosing of 
crizotinib. The plasma concentrations of crizotinib were 1.3, 1.5, and 1.3 μg/mL at 2, 4, 
and 8 h after 14-day repeated oral administration at 30 mg/kg in mice with intra-hepatic 
xenografts (data not shown). In patients with ALK fusion-positive NSCLC, the median 
trough concentration of crizotinib at steady state is reported to be approximately 0.3 
μg/mL (45). Based on the reported clinical data, my colleagues and I consider that 
sufficient drug exposure was achieved in mice administered 30 mg/kg crizotinib. In the 
two xenograft models, treatment with 30 mg/kg ASP3026 induced continuous tumor 
reduction, indicating that ASP3026 has potential efficacy against metastatic lesions in 
patients refractory to crizotinib, although this conclusion should be re-evaluated once 
pharmacokinetic data in humans becomes available. 
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The gatekeeper-residue mutation L1196M of ALK was initially found in ALK-
positive NSCLC patients who relapsed after an initial response to crizotinib (39, 46-48). 
In the present experiments, crizotinib exhibited 10-fold weaker inhibitory activity 
against EML4-ALK with L1196M compared to wild-type EML4-ALK, and no 
inhibitory activity was detected in a xenograft model at an oral daily dose of 100 mg/kg, 
as was shown in previous reports (35, 36). The inhibitory activity of ASP3026 was 
approximately 3-fold weaker for EML4-ALK with the L1196M mutation, but in the 
xenograft model, ASP3026 also induced tumor regression in cells expressing this 
gatekeeper-residue mutant as well as wild-type EML4-ALK. In addition, computation 
modeling suggested that ASP3026 fits more deeply within the ATP-binding pocket of the 
gatekeeper-residue mutant form of EML4-ALK than crizotinib, which might explain 
why ASP3026 showed more potent efficacy within the therapeutic margin compared 
with crizotinib. 
ASP3026 induced rapid tumor regression in subcutaneous, intrapleural, and intra-
hepatic NCI-H2228 xenograft and transgenic mouse models. In these models, tumors 
rapidly decreased in size during the first 10 days of treatment with ASP3026, but the 
tumor regression then slowed. In the xenograft models, tumors were detectable at the 
end of each treatment period, with the size of the remaining tumors exhibiting a 
dependence on the dose of ASP3026. When the remaining tumors were again grown and 
treated with ASP3026 after a washout period of 3 weeks, the tumors rapidly decreased 
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in size (data not shown), indicating that the remaining tumor cells are considered to retain 
ALK fusion kinases. Although the mechanism underlying the reduced rate of tumor 
regression is unknown, it is possible that alternative pathways, such as those involving 
other tyrosine kinases, are upregulated in the residual tumors. In patients refractory to 
crizotinib, the EGFR pathway is activated due to EGFR upregulation, active mutation of 
EGFR, and increased ligand concentrations in pleural effusion (46-48). In addition, KIT 
gene amplification and KRAS mutation were also found in crizotinib refractory patients, 
suggesting that several alternative pathways are possibly involved in the refractory 
response (46, 47). The findings of several preclinical studies also indicate that alternative 
pathways may play an important role in resistance to crizotinib. For example, several 
EGFR ligands, including EGF, TGF-α, and HB-EGF, triggered resistance to ALK 
inhibitors against ALK-dependent cells (49), and coactivation of EGFR signaling was 
observed in ALK inhibitor-resistant H3122 cells (50). Tanizaki and colleagues (51) also 
demonstrated that EGF-mediated activation of HER family signaling is associated with 
ALK-TKI resistance in lung cancer positive for EML4-ALK. Thus, the combination 
therapy of ASP3026 with inhibitors targeting alternative pathways, such as EGFR, might 
lead to complete tumor regression. In the preliminary experiments, NCI-2228 cells 
resistant to ASP3026 developed after long-term culture in the presence of 500 to 1000 
nM ASP3026. Elucidation of the resistance mechanism may help determine suitable 
mechanism-based medicines for treating patients resistant to ASP3026.  
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In the present study, ASP3026 enhanced the antitumor activity of paclitaxel and 
pemetrexed in a NCI-H2228 subcutaneous xenograft model, but did not synergistically 
enhance the activity of carboplatin. Although the reason for this latter result is unknown, 
importantly, ASP3026 did not enhance the toxicity of these NSCLC drugs. Increasing 
evidence for intratumor genetic heterogeneity is accumulating, both within individual 
tumor biopsies and between spatially separated biopsies of the same tumor, suggesting 
that solid cancer is generally heterogeneous (52, 53). As patients with ALK fusion-
positive tumors are also likely to have fusion-negative tumors, the combination of 
ASP3026 with conventional antitumor drugs may provide therapeutic benefits to patients. 
Notably, however, the combination of a targeted tyrosine kinase inhibitor such as 
ASP3026 with cytostatic anticancer agents has not yet been proven to be generally 
effective and further examination of patient-derived xenografts is necessary to evaluate 
the potential benefits of such combination therapy. 
In conclusion, ASP3026 selectively inhibits ALK kinases and has high antitumor 
activity and tumor penetration against ALK-driven tumors, leading to prolonged survival. 
ASP3026 also has a wide therapeutic margin between efficacious and toxic doses, and 
exhibits efficacy against crizotinib-refractory tumors. Notably, combining ASP3026 
with antitumor agents enhances the activity of these compounds. My colleagues and my 
findings demonstrate that ASP3026 functions as a novel ALK inhibitor and is expected 
to improve the therapeutic outcomes of cancer patients with ALK abnormality.  
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Tables 
 
Table 1. Inhibitory activity of ASP3026 and crizotinib against various TKs
 
Inhibitory assay for a panel of tyrosine kinases was conducted using a TK-ELISA or Off-
chip MSA. Percent inhibitions were determined in a single experiment.
Kinase
% Inhibition
Kinase
% Inhibition
ASP3026 Crizotinib ASP3026 Crizotinib
0.1 μM 1 μM 0.1 μM 1 μM 0.1 μM 1 μM 0.1 μM 1 μM
ABL 9.8 57.2 51.4 92.6 FMS 74.0 97.3 55.2 95.8 
ACK 100.3 101.4 22.4 77.1 FRK 73.1 97.0 5.4 48.2 
ALK 99.2 102.1 101.7 100.9 FYN 45.4 91.2 13.3 67.7 
ALK(F1174L) 89.6 101.4 99.9 99.8 HCK 15.8 68.5 1.9 38.5 
ALK(R1275Q) 97.6 103.0 100.4 102.1 HER2 -3.0 -2.3 -4.4 -4.7 
ARG 14.8 63.0 47.8 92.1 HER4 22.4 72.0 -1.7 1.9 
AXL 10.9 56.0 97.2 100.6 IGF1R 30.9 83.8 42.2 91.1 
BLK 14.5 62.5 16.5 72.6 INSR 36.2 88.0 56.4 95.6 
BMX 10.5 38.0 6.9 59.0 IRR 35.4 87.7 68.5 97.9 
BRK 34.2 84.6 2.0 27.4 ITK -2.5 14.2 17.4 78.8 
BTK 10.8 48.0 -3.5 13.4 JAK1 -2.7 -1.5 15.7 69.1 
CSK 4.3 30.3 -3.9 15.9 JAK2 0.9 3.1 85.2 99.8 
CTK -0.2 2.1 1.9 3.8 JAK3 2.0 3.2 30.2 84.9 
DDR1 75.1 98.8 81.1 99.1 KDR 1.7 6.7 6.6 57.5 
DDR2 42.8 91.7 60.4 96.0 KIT 4.1 18.0 -5.4 6.6 
EGFR 24.1 69.2 -7.9 3.0 LCK 31.9 81.3 87.3 100.6 
EGFR(L858R) 51.7 89.8 -5.2 8.4 LTK 57.7 98.4 100.4 101.4 
EGFR(L861Q) 15.8 68.4 -3.4 -0.5 LYNa 11.9 55.6 10.0 53.6 
EGFR(T790M) 7.1 42.3 -3.6 0.6 LYNb 8.9 49.9 8.4 50.5 
EGFR(T790M/L858R) 41.7 88.5 -3.2 4.9 MER 11.8 48.5 96.6 100.5 
EPHA1 59.3 93.9 90.4 100.4 MET 0.5 18.3 98.9 99.9 
EPHA2 7.2 45.0 60.9 95.0 MUSK 14.8 68.8 94.3 100.6 
EPHA3 -0.6 3.6 3.7 37.2 NPM1-ALK 96.6 102.8 102.2 100.3 
EPHA4 3.4 28.1 23.1 76.9 PDGFRa 18.0 70.0 2.6 42.3 
EPHA5 3.1 29.2 30.3 83.0 PDGFRb 23.7 80.4 -5.1 19.5 
EPHA6 0.2 2.9 61.8 99.8 PYK2 56.4 93.4 76.0 98.0 
EPHA7 -0.4 12.3 37.1 87.9 RET -2.6 6.9 8.9 62.9 
EPHA8 -0.5 5.9 43.2 90.4 RON 4.6 12.2 97.1 101.9 
EPHB1 32.9 83.7 75.4 99.4 ROS 92.4 101.5 102.2 102.1 
EPHB2 8.5 48.6 26.1 80.4 SRC 27.9 69.7 25.1 75.0 
EPHB3 1.2 29.4 -1.9 6.8 SRM 5.9 40.7 -2.0 1.6 
EPHB4 7.5 45.9 55.3 92.6 SYK 0.0 17.9 27.3 76.1 
FAK 65.8 95.8 72.6 93.9 TEC -2.9 14.5 -5.5 9.9 
FER 59.5 95.7 66.8 99.4 TIE2 3.2 24.8 24.9 79.8 
FES 42.6 90.2 64.0 97.8 TNK1 78.7 98.6 10.0 57.2 
FGFR1 0.9 26.6 -0.5 34.6 TRKA -4.7 13.6 98.2 101.3 
FGFR2 4.5 33.3 9.6 58.2 TRKB -3.8 0.4 94.2 100.6 
FGFR3 3.0 30.5 10.5 64.3 TRKC 2.9 1.0 93.6 100.8 
FGFR4 -2.5 5.1 -4.9 2.4 TXK 5.3 16.7 11.4 58.6 
FGR 26.7 73.0 33.7 83.7 TYK2 -0.1 -0.8 1.3 40.1 
FLT1 4.7 12.3 11.6 70.7 TYRO3 3.3 14.5 81.0 98.6 
FLT3 25.9 75.0 10.9 61.6 YES 70.7 98.2 24.5 75.4 
FLT4 4.3 31.6 1.3 48.6 ZAP70 0.2 -0.9 2.6 39.1 
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Table 2. Inhibitory activity of ASP3026 against various tyrosine kinases. 
 
Inhibitory assay for the indicated tyrosine kinases (TK) was conducted using a TK-
ELISA or Off-chip MSA. IC50 values were determined for TKs that were inhibited by 
more than 50% at 100 nM in 3 individual experiments.  
TK
IC50 (nM)
TK
IC50 (nM)
ASP3026 Crizotinib ASP3026 Crizotinib
wt ALK 3.5 1.5 LTK 61 1.8
F1174L ALK 10 1.8 MER >1000 3.4
R1275Q ALK 5.4 2 MET >1000 1.5
NPM1-ALK 6.8 2 MUSK >100 9.1
ACK 5.8 >100 RON >1000 5.5
AXL >100 3.3 ROS 8.9 0.95
L858R EGFR 86 >1000 TNK1 26.8 >100
EPHA2 >1000 54 TRKA >1000 3.2
EPHA6 >1000 54 TRKB >1000 4.6
EPHB4 >1000 68 TRKC >1000 4.4
FRK 40 >1000 TYRO3 >1000 20
JAK2 >1000 11 YES 31.5 >100
LCK >100 11
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Table 3. Inhibition of ALK phosphorylation and signal transduction in NCI-H2228 cells 
by ASP3026 
 
NCI-H2228 cells were treated with ASP3026 at the indicated concentrations for 4 h, and 
each protein was detected by immunoblotting using specific antibodies. The numbers 
represent the mean percent of phosphorylated protein/total protein relative to that in 
vehicle-treated cells. ∗∗: P<0.01, ∗∗∗: P<0.001 compared with the value of the vehicle-
treated group (Dunnett’s test).  
Treatment
Control 100% 100% 100% 100%
ASP3026 10 nM 70% ** 120% 101% 88%
ASP3026 100 nM 37% *** 56% *** 54% *** 52% ***
ASP3026 1000 nM 9% *** 20% *** 36% *** 46% ***
pALK pAKT pERK pSTAT3
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Table 4. Pharmacokinetic parameters of ASP3026 after 5-day repeated oral dosing of 
ASP3026 in NOD/SCID mice xenografted with NCI-H2228 cells 
 
  
Cmax Tmax AUC0-24h Cmax Tmax AUC0-24h
(ng/mL) (h) (ng·h/mL) (ng/g) (h) (ng·h/g)
1 44.3 4 630 850 4 13600 19 22
3 140 4 1820 2270 4 34400 16 19
10 508 4 5990 8990 4 121000 18 20
Dose
(mg/kg/day)
Plasma Tumor
Ratio of
tumor/plasma
Cmax AUC0-24h
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Table 5. Inhibitory activity of ASP3026 against EML4-ALK with gatekeeper-residue 
mutation L1196M 
 
(A) Kinase activities of EML4-ALK variant 1 kinase (wild-type) and its L1196M-
mutated form were measured with HTRF® KinEASE™-TK in the presence of ASP3026 
or crizotinib. Data represent IC50 values of the compounds against both kinases, and the 
ratio of IC50 value for mutated versus wild type EML4-ALK. (B) 3T3 cells expressing 
either wild-type or mutated EML4-ALK were seeded and cultured for 1 day. Cells were 
then treated with ASP3026 or crizotinib for two days, and viable cell numbers were 
determined by the CellTiter-GloTM Luminescent Cell Viability Assay. Data represent 
IC50 values of the compounds for both cell types, and the ratio of IC50 value for mutant-
expressing versus wild type-expressing cells.  
Assay Compound
IC50 (nM) Ratio
(L1196M/WT)EML4-ALK
wild-type (WT)
EML4-ALK
L1196M
(A) Kinase Inhibition
ASP3026 10 32 3.2
Crizotinib 5 51 10
(B) Growth Inhibition 
of 3T3 cells
ASP3026 42 163 3.9
Crizotinib 45 413 9.2
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Figures 
 
Fig. 1. Structure and in-vitro ALK inhibitory activity of ASP3026. (A) Chemical 
structure of ASP3026. (B) Anti-proliferative activity of ASP3026 against NCI-H2228 
NSCLC cells expressing EML4-ALK. The cells were seeded on spheroid plates and 
treated with various concentrations of ASP3026 for 5 days. Viable cell number was 
determined by the CellTiter-GloTM Luminescent Cell Viability Assay to assess growth 
inhibition and is expressed as relative light units. Each point represents the mean relative 
luciferase units of triplicate replicates. The data is representative of four independent 
experiments. (C) Inhibition of ALK phosphorylation and signal transduction in NCI-
H2228 cells by ASP3026. NCI-H2228 cells were treated with ASP3026 at the indicated 
concentrations for 4 h, and each protein was detected by immunoblotting using specific 
antibodies. 
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Fig. 2. Antitumor activities of ASP3026 in a NCI-H2228 xenograft model and hEML4-
ALK transgenic mice. (A) Inhibition of ALK phosphorylation in NCI-H2228 tumors by 
ASP3026. Mice with NCI-H2228 tumors were treated with ASP3026 as a single oral 
dose of 10 mg/kg. After 4 h, tumors were excised, and total and phosphorylated EML4-
ALK were detected by immunoblotting. The numbers represent the mean percent of 
phosphorylated protein/total protein relative to that in the vehicle-treated group.  
∗∗∗: P<0.001 compared with the value of the vehicle-treated group (Student’s t-test). (B) 
Subcutaneously xenografted mice with NCI-H2228 cells were treated with once-daily 
oral administration of ASP3026 at the indicated doses for two weeks. Tumor volume and 
body weight were measured to assess antitumor activity. Each point represents the mean 
± SEM, and the number of animals used is shown in parentheses. The values obtained 
on day 14 were statistically analyzed and compared. ∗∗: P<0.01 compared with the value 
of the control group on day 14 (Dunnett’s test). (C) ASP3026 concentrations in plasma 
and tumors after 5-day repeated oral dosing of ASP3026 at the indicated doses in mice 
with NCI-H2228 tumors were measured using high-performance liquid 
chromatography-tandem mass spectrometry. Each point represents the mean ± SEM of 
three individual mice. (D) hEML4-ALK transgenic mice were treated with once-daily 
oral administration of ASP3026 at the indicated doses for 11 days. CT acquisition data 
were reconstructed using Inveon Acquisition Workplace software to determine tumor 
volume. Each point represents the mean ± SEM (n=3-4). ∗∗: P<0.01, ***: P<0.001 
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compared with the value of the control group by two-way ANOVA followed by 
Bonferroni's multiple comparison test. n.d.: not detected. 
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Fig. 3. Antitumor activity of twice-daily oral dosing of ASP3026 at 100 mg/kg in a NCI-
H2228 xenograft model. Tumor volume (A) and body weight (B) were measured to 
assess antitumor activity. Each point represents the mean ± SEM (n=6). ∗∗: P<0.01 
compared with the value of the control group on day 14 (Student’s t-test). NS: not 
significant 
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Fig. 4. Antitumor activities of ASP3026 in hEML4-ALK transgenic mice. hEML4-ALK 
transgenic mice were treated with once-daily oral administration of ASP3026 at the 
indicated doses for 11 days. The tumors were monitored by computed tomography scan. 
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Fig. 5. Antitumor activity of ASP3026 in combination with antitumor agents against 
NCI-H2228 tumors. Oral ASP3026 was given once daily at 10 mg/kg in combination 
with (A) paclitaxel (intravenous, 12 mg/kg, days 0-4), (B) pemetrexed (intravenous, 50 
mg/kg, days 0-4), or (C) carboplatin (intravenous, 60 mg/kg, days 0 and 7). Tumor 
volume and body weight were measured to assess antitumor activity. Each point 
represents the mean ± SEM (n=4-5). Values obtained on the last day of each experiment 
were statistically analyzed and compared. ∗: P<0.05, ∗∗: P<0.01 compared with the 
ASP3026 single-treatment group, +: P<0.05, ++: P<0.01 compared with each 
combination partner (Student’s t-test). NS: not significant. 
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Fig. 6. Antitumor activity of ASP3026 against tumors in the pleural cavity and liver. (A) 
H2228-luc cells were directly inoculated into the pleural cavity of NOD/SCID mice. 
ASP3026 and crizotinib were orally administered once daily for 7 weeks at doses ranging 
from 3 to 30 mg/kg starting at 14 days after cell inoculation (n=10). The survival of mice 
was monitored daily, and the median survival time was determined for each group. *: 
P<0.05, **: P<0.01 compared with the value of the control group by the log-rank test. 
(B) ASP3026 and crizotinib were administered to NOD/SCID mice implanted with 
H2228-luc cells as in (A), and the implanted cells were monitored using BLI of the chest 
area. Each point represents the mean BLI ± SEM (n=8). (C) H2228-luc cells were 
inoculated into the portal vein of NOD/SCID mice. After confirming tumor growth, 
ASP3026 and crizotinib were orally administered once daily for three weeks at the 
indicated doses. Each point represents the mean BLI ± SEM from each animal (n=8). 
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Fig. 7. Growth of H2228-luc cells directly inoculated into the pleural cavity of 
NOD/SCID mice. (A) The implanted cells were monitored using BLI of the chest area 
after luciferin injection. Each point represents the mean ± SEM (n=4-5). (B) Photographs 
overlayed with the imaging data at the indicated days. (C) Photographs overlayed with 
the imaging data from mice orally administered ASP3026 and crizotinib once daily for 
23 days at the indicated doses. Dotted signals seen in control and ASP3026 10 mg/kg 
groups are noises in the imaging system. 
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Fig. 8. Growth of H2228-luc cells in livers after inoculation into the portal vein of 
NOD/SCID mice. (A) The implanted cells were monitored using BLI of the abdominal 
area after luciferin injection. Each point represents the mean ± SEM (n=4). (B) 
Photographs overlayed with the imaging data at the indicated days. (C) Photographs 
overlayed with the imaging data from mice orally administered ASP3026 and crizotinib 
once daily for 19 days at the indicated doses. 
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Fig. 9. Antitumor activity of ASP3026 against tumor cells expressing a gatekeeper-
residue mutant of EML4-ALK, and binding modes of ASP3026 and crizotinib with wild-
type and L1196M ALKs. EML4-ALK/3T3 (A) and EML4-ALK L196M/3T3 cells (B) 
were subcutaneously inoculated into nude mice, and ASP3026 and crizotinib were then 
administered to mice as a daily oral dose of 100 mg/kg/day for 5 days. Tumor volume 
was measured to assess antitumor activity. Each data point represents the mean ± SEM 
(n=4). ∗∗: P<0.01 compared with the value of the control group on day 5 (Dunnett’s test). 
(C) ASP3026 and crizotinib are shown as ball-and-stick models and the gatekeeper 
residues (L1196 and M1196) are drawn as vdW spheres. Atoms are colored by element: 
white, hydrogen; cyan, carbon of ligands; gray, carbon of proteins; blue, nitrogen; red, 
oxygen; and yellow, sulfur). The protein surface is colored based on electrostatic 
potential (blue, positive; red, negative; and white, neutral). For clarity, non-polar 
hydrogen atoms are omitted and the protein surfaces lying anterior to the gatekeeper 
residues are hidden. G1202, E1210, and S1206 are potential interactive sites with the 
piperidine ring of crizotinib and the piperazine ring of ASP3026. The K1150 residue 
forms a hydrogen bond with the sulfonyl group of ASP3026. 
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Part II 
 
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of 
FLT3 mutated acute myeloid leukemia 
  
 54 
 
Abstract 
Advances in the understanding of the molecular basis for acute myeloid leukemia 
(AML) have generated new potential targets for treatment. Fms-like tyrosine kinase 3 
(FLT3) is one of the most frequently mutated genes in AML and mutations in this gene 
are associated with poor overall survival. AXL plays a role in the activation of FLT3 and 
has been implicated in the pathogenesis of AML. The studies reported here evaluated the 
ability of a novel FLT3/AXL inhibitor, gilteritinib, to block mutated FLT3 in cellular and 
animal models of AML. Initial kinase studies showed that gilteritinib, a type I tyrosine 
kinase inhibitor, was highly selective for both FLT3 and AXL while having weak activity 
against c-KIT. Gilteritinib demonstrated potent inhibitory activity against the internal 
tandem duplication (FLT3-ITD) and FLT3-D835Y point mutations in cellular assays 
using MV4-11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. 
Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these 
assays. Furthermore, gilteritinib decreased the phosphorylation levels of FLT3 and its 
downstream targets in both cellular and animal models. In vivo, gilteritinib was 
distributed at high levels in xenografted tumors after oral administration. The decreased 
FLT3 activity and high intratumor distribution of gilteritinib translated to tumor 
regression and improved survival in xenograft and intra-bone marrow transplantation 
models of FLT3-driven AML. No overt toxicity was seen in mouse models treated with 
gilteritinib. These results indicate that gilteritinib may be an important next-generation 
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FLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML. 
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Introduction 
AML is a rapidly progressing hematologic cancer characterized by loss of normal 
differentiation and uncontrolled proliferation of hematopoietic progenitor cells in the 
bone marrow (54). This dysregulation of blood cell production leads to anemia, 
neutropenia, and thrombocytopenia (54). First-line treatment for patients (aged ≤60 
years) with AML often begins with a cytarabine- and anthracycline-based chemotherapy 
regimen through remission induction and post-remission phases. While the complete 
remission rate for patients who undergo this line of treatment is over 70% (54), the 5-
year survival rate is still only 50% (55). Age and leukemia cytogenetics affect patient 
response rate (55-58), and therapeutic outcomes are worse for patients who are not 
eligible for the intensive treatment or who are relapsed/refractory to front-line therapy 
(59, 60). A number of advances have been made in understanding the genetics behind 
AML (55, 56) that may lead to new opportunities for the development of targeted 
therapies. 
FLT3 is a member of the class III receptor tyrosine kinase (TK) family that is normally 
expressed on the surface of hematopoietic progenitor cells (61). The FLT3 receptor plays 
an important role in proliferation, survival, and differentiation of multipotent stem cells 
(61), and mutations of FLT3 are the most common molecular alteration in AML. ITDs 
at the juxtamembrane domain within FLT3 are present in 25–30% of newly diagnosed 
AML cases (62-65), representing the most frequent FLT3-activating mutation. 
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Activating point mutations within the FLT3 TK domain (TKD) are also observed in 
patients with AML, but with less frequency than ITD mutations (64, 66). These 
activating mutations are oncogenic and are associated with poor prognosis, higher 
relapse rate, more rapid time to relapse, reduced disease-free survival, and reduced 
overall survival, although the prognostic impact for FLT3-TKD mutations is 
controversial (64-68). Overall, these findings suggest that FLT3 is a potential therapeutic 
target for patients with AML who are harboring a FLT3 mutation. 
Similar to FLT3, AXL (a member of the TAM family of receptor TKs) has 
transforming properties and has been identified as a potential therapeutic target for AML 
(69, 70). Preclinical studies showed that inhibition of AXL blocks proliferation of FLT3 
mutant and FLT3 wild-type AML cells and also suppresses the leukemic burden of FLT3-
ITD+ AML in both a subcutaneous xenograft model and a leukemia engraftment model 
(69-71). Furthermore, activated AXL may be required for resistance to FLT3 inhibitors 
(72). Therefore, a new chemical entity that targets both FLT3 and AXL may provide a 
novel treatment option for AML.  
Gilteritinib is a small-molecule FLT3/AXL inhibitor with a structure based on a 
pyrazine carboxamide scaffold. The research described here aimed at characterizing the 
activity of gilteritinib against FLT3-driven AML in preclinical models to elucidate the 
potential as an anticancer drug candidate prior to initiation of the clinical trial and also 
to reveal the role of the aberrant kinase in cancer biology. The inhibitory effects of 
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gilteritinib against FLT3 were assessed in cell-free systems and cellular assays, and its 
antitumor activity and survival benefits were evaluated in FLT3-driven tumors in mice. 
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Materials and Methods 
Compounds, cell lines, and antibodies 
Gilteritinib hemifumarate (referred to herein as gilteritinib), also known as ASP2215 
hemifumarate, and quizartinib are small-molecule TK inhibitors (TKI) synthesized by 
Astellas Pharma Inc. (Tokyo, Japan). Gilteritinib and quizartinib were dissolved in 
DMSO or suspended in 0.5% methylcellulose for in vitro or in vivo experiments, 
respectively. MV4-11 cells were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA); MOLM-13 cells were purchased from the German Collection 
of Microorganisms and Cell Cultures (Braunschweig, Germany). MV4-11-luc cells, 
which exogenously express firefly luciferase, were prepared at Astellas Pharma Inc. (a 
detailed protocol for the generation of the constructs is found in the online resource). 
MV4-11-AXL cells, which exogenously express AXL, were also prepared at Astellas 
Pharma Inc. Ba/F3 cells expressing FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-
ITD-F691L, or FLT3-ITD-F691I mutations (FLT3-ITD_Ba/F3, FLT3-D835Y_Ba/F3, 
FLT3-ITD-D835Y_Ba/F3, FLT3-ITD-F691L_Ba/F3, FLT3-ITD-F691I_Ba/F3) were 
established by Astellas Pharma Inc. The following antibodies were used for 
immunoblotting: FLT3 (Abcam, Cambridge, MA); phosphorylated pan-tyrosine (Merck 
Millipore, Billerica, MA); p44/42 MAPK (ERK1/2), phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (197G2) (E10), AKT, phospho-AKT (Ser473) (193H12), and AXL 
(C44G1) (Cell Signaling Technology, Danvers, MA); STAT5 and phospho-STAT5 
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(Y694) (BD Biosciences, Franklin Lakes, NJ); phospho-AXL (Y779) (MAB6965, R&D 
systems, Minneapolis, MN); and β-actin (Sigma-Aldrich, St. Louis, MO). 
Kinase inhibitory assays 
The kinase inhibitory activity of gilteritinib was tested against a panel of 78 TKs 
(Table 6) using ATP concentrations that were approximately equal to the Km value for 
each kinase in a TK-ELISA or off-chip mobility shift assay (MSA) at Carna Biosciences, 
Inc. (Kobe, Japan). These assays were conducted according to the manufacturer’s 
instructions. Initially, two concentrations of gilteritinib (1 nM and 5 nM) were tested to 
assess each compound’s inhibitory effect on TK activity. Further studies were then 
conducted using a dose range of gilteritinib to determine IC50 values for kinases in which 
activity was inhibited by >50% with 1 nM gilteritinib as well as for c-KIT. TK-ELISA 
and MSA assays were used to conduct IC50 studies for FLT3, LTK, AXL, and c-KIT; the 
HTRF® KinEASE™-TK assay (Sceti Medical Labo, Tokyo, Japan) was performed 
according to the manufacturer’s protocol to assess the IC50 value of echinoderm 
microtubule-associated protein-like 4-ALK (EML4-ALK; three individual experiments 
for each kinase).  
Cell viability assays 
To examine the effect of ASP2215 on cell viability, MV4-11, MOLM-13, and Ba/F3 
cells expressing either FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691L 
or FLT3-ITD-F691I were seeded into 96-well white plates (Nunc F96 MicroWell™ 
 61 
 
Plates, white; Thermo Fisher Scientific Inc., Waltham, MA) at 1000 cells/well in Iscove’s 
Modified Dulbecco’s Medium, 500 cells/well in RPMI 1640 or 1000 cells/well in RPMI 
1640, respectively. All cell lines were cultured overnight in a humidified incubator at 
37°C with 5% CO2 in media supplemented with 10% heat-inactivated FBS. Cell viability 
was determined for MV4-11 and MOLM-13 cells after 5 days of treatment with a dose 
course of gilteritinib; viability of Ba/F3 cells and cells expressing mutant FLT3 was 
assessed after treatment for 2 days with a dose course of gilteritinib and quizartinib. An 
additional study was conducted in Ba/F3 cells treated with both gilteritinib and IL-3 (1 
ng/mL) to ascertain off-target effects of gilteritinib. 
After treatment, the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was 
used according to the manufacturer’s instructions and luminescence was measured using 
an ARVO-HTS plate reader (Perkin Elmer Inc., Waltham, MA). The assay was 
performed in either triplicate or quadruplicate. The effect of gilteritinib on cell 
proliferation was analyzed using SAS software (SAS Institute Inc., Cary, NC), Microsoft 
Excel (Microsoft), or GraphPad Prism (GraphPad Software), and the IC50 value of each 
experiment was calculated via Sigmoid-Emax model non-linear regression analysis. The 
geometric mean was calculated from three individual experiments. 
Preparation of Ba/F3 constructs 
The mutants of FLT3 (NM_004119), FLT3-D835Y (gat to tat), FLT3-ITD (insertion 
of acgttgatttcagagaatatgaatatgatc at 1799 position of CDS), FLT3-ITD-F691I (ttt to att), 
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FLT3-ITD-F691L (ttt to ctt), FLT3-ITD-D835Y were encoded into pMX-puro vector 
(Cell Biolabs, Inc., San Diego, CA), and transfected with FuGENE-HD (Promega) into 
Platinum-E cells. The next day, the culture medium was changed and cultured for 72 h, 
and the culture medium were recovered and filtrated. Ba/F3 cells were infected with a 
retroviral vector for 6 h and cultured in the growth medium for 3 days. After the drug 
selection with puromycin at 1.5 μg/mL for 3 days, cells were cultured in the growth 
medium minus IL-3. 
FLT3 immunoprecipitation 
For the immunoprecipitation of FLT3, MV4-11 cells were seeded into 6-well plates 
at 5×106 cells/well and cultured for 1 day prior to treatment. Following 2 h of treatment 
with either DMSO or a dose range of gilteritinib (0.1–10 nM), cells were lysed in RIPA 
buffer (Thermo Fisher Scientific) containing phosphatase and protease inhibitors, and 
the subsequent cell lysate was sonicated and centrifuged to pellet debris. Cell lysates 
(500 μg) were incubated with an anti-FLT3 antibody sc-480 (Santa Cruz Biotechnology, 
Santa Cruz, CA) overnight at 4°C and then incubated for 2 h with 20 μL Protein G 
Sepharose™ 4 Fast Flow (GE Healthcare, Fairfield, CT). The beads were washed with 
lysis buffer and boiled for 5 min in a 1 × SDS sample buffer (Wako Pure Chemical 
Industries, Osaka, Japan). Samples were electrophoresed on 7.5% gels and transferred 
to PVDF membranes. 
Detection of downstream FLT3 targets and AXL 
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For the detection of ERK, STAT5, and AKT and their phosphorylated forms, MV4-
11 cells were seeded at 1×106 cells/well in 6-well plates (AGC Techno Glass, Shizuoka, 
Japan) and cultured for 1 day prior to treatment with either DMSO or a dose range of 
gilteritinib (0.1–10 nM). Cells were treated for 2 h prior to cell lysate preparation in 
RIPA buffer supplemented with phosphatase and protease inhibitors. Following sample 
preparation, protein lysates were electrophoresed on 7.5% gels and transferred to PVDF 
membranes. 
For the detection of AXL and phospho-AXL, MV4-11-AXL cells were seeded at 
1×106 cells/well in 10-cm dish and cultured for 1 day prior to treatment with either 
DMSO or a dose range of gilteritinib (1–100 nM). Cells were treated for 4 h prior to cell 
lysate preparation in RIPA buffer supplemented with phosphatase and protease inhibitors. 
Following sample preparation, protein lysates were electrophoresed on 7.5% gels and 
transferred to PVDF membranes. 
Immunoblotting 
All membranes were blocked using either Blocking One or Blocking One-P (Nacalai 
Tesque Inc., Kyoto, Japan) for 1 h prior to an overnight incubation with primary antibody. 
Membranes were incubated overnight at 4°C with one of the following antibodies: anti-
FLT3 antibody (Abcam), anti-phosphorylated pan-tyrosine, anti-ERK, anti-phospho-
ERK, anti-STAT5, anti-phospho-STAT5, anti-AKT, anti-phospho-AKT, anti-AXL, anti-
phospho-AXL, or anti-actin. The membranes were then washed with 1× TBS-T Buffer 
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and incubated with an appropriate HRP-linked secondary antibody (Cell Signaling 
Technology) for 1 h at room temperature. After a final wash, ECL Western Blotting 
Detection Reagent ECL-prime (GE Healthcare, Fairfield, CT) were applied to the 
membranes and signals were detected with a CCD camera (ImageQuant LAS4000; GE 
Healthcare). Signal intensity was then quantified using ImageQuant™ TL software (GE 
Healthcare). The study was performed once in triplicate, and the mean percentage of 
phosphorylated protein to total protein relative to that in vehicle-treated cells was 
calculated. 
Detection of phospho-FLT3 and downstream targets in Ba/F3 cells expressing 
mutant FLT3. 
To detect phosphorylated FLT3 and its downstream targets in Ba/F3 cells expressing 
mutant FLT3, cells were seeded at 6×106 cells per 10 cm dish and cultured overnight 
prior to treatment. Cells were treated with either DMSO or 0.1 nM, 1 nM, or 10 nM 
gilteritinib for 2 h. Cells were lysed in RIPA buffer and blotted for target proteins of 
interest as described earlier. Densitometry data normalized to total protein and then to 
the mean vehicle control for each target. Mean values reported from triplicate points. 
Animal models for in vivo studies 
All animal experimental procedures were approved by the Institutional Animal Care 
and Use Committee of Astellas Pharma Inc., and the Tsukuba Research Center of 
Astellas Pharma Inc. was awarded accreditation status by AAALAC International. Mice 
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were maintained on standard diet and water throughout experimental procedures.  
In vivo mouse xenograft model 
For studies examining the in vivo kinase inhibitory activity of gilteritinib, male nude 
mice (CAnN.Cg-Foxn1nu/CrlCrlj[nu/nu]) (Charles River Laboratories Japan, Inc., 
Kanagawa, Japan), that were 5 weeks old, were subcutaneously inoculated with MV4-
11 cells (5×106 cells/mouse) on day 0. After 1 month, mice were divided into groups, 
with each group having approximately the same mean tumor volume. Mice with MV4-
11 tumors were treated with a single oral dose of gilteritinib (1 mg/kg, 3 mg/kg, 6 mg/kg, 
or 10 mg/kg) and tumors were excised 1 h, 2 h, 4 h, 8 h, and 24 h after administration.  
For in vivo xenograft studies on gilteritinib antitumor activity, MV4-11 cells (5×106 
cells/mouse) or Ba/F3 cells expressing a FLT3-ITD, FLT3-D835Y, or FLT3-ITD-D835Y 
mutation (3×106 cells/mouse) were subcutaneously injected into the flank of male nude 
mice at 7 weeks old (MV4-11) or 4 weeks old (Ba/F3) (Charles River Laboratories). 
After tumor establishment, mice were divided into groups such that the mean tumor 
volume was approximately equal in each group. Mice were then orally administered 
either 0.5% methylcellulose or once-daily gilteritinib suspended in a 0.5% 
methylcellulose solution at doses of 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg (MV4-
11) or 10 mg/kg and 30 mg/kg (Ba/F3). 
Tumor diameter was measured using a caliper, and tumor volume was determined by 
calculating the volume of an ellipsoid using the formula: length × width2 × 0.5. Body 
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weight was measured using a standard balance. Data are expressed as mean ± SEM from 
n=6 mice/group (MV4-11) and n=5 mice/group (Ba/F3). 
ELISA for phosphorylated-FLT3 and total FLT3 
MULTI-ARRAY® 96-well plates (Meso Scale Discovery, Rockville, MD) were coated 
with capture antibodies for phosphorylated FLT3 or total FLT3 (DuoSet® IC, R&D 
systems, Minneapolis, MN) and incubated overnight at 4°C with shaking. After washing 
with TBS-T, coated plates were blocked with 3% MSD® Blocker-A (Meso Scale 
Discovery) in TBS-T for 1 h at room temperature and then incubated with total protein 
lysates derived from MV4-11 xenografted tumors (500 μg/well for phosphorylated FLT3 
and 20 μg/well for FLT3), overnight at 4°C. Following a wash step, anti-phosphotyrosine 
antibody (clone 4G10®, Biotin Conjugate [Millipore, Billerica, MA]) for the detection 
of phosphorylated FLT3 or the DuoSet® IC FLT3 detection antibody for total FLT3 were 
added to the plate and incubated for 2 h at room temperature. Wells were then washed 
and incubated with MSD® SULFO-TAG Labeled Streptavidin (Meso Scale Discovery) 
for 1 h at room temperature, followed by the addition of MSD® Read Buffer (Meso Scale 
Discovery). Electrochemiluminescent signals were measured using a SECTOR® imager 
(Meso Scale Discovery). Phosphorylation levels were normalized to total FLT3 levels in 
each group (3 mice/group except the point at 1 h after the administration of 1 mg/kg [2 
mice]) relative to the mean value of the control group (5 mice/group). Data are reported 
as mean ± SEM. 
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Immunoblot for phosphorylated-STAT5 and STAT5 in xenograft mouse model 
MV4-11 xenograft tumor protein samples were electrophoresed on 7.5% gels, 
transferred to PVDF membranes, and probed for phosphorylated-STAT and total STAT5 
as described earlier with one alteration. Following detection of phosphorylated STAT5, 
the membrane was stripped using Restore™ Western Blot Stripping Buffer (Thermo 
Fisher Scientific) and then re-probed for total STAT5. Phosphorylation levels were 
normalized to total STAT5 levels in each group (3 mice/group) relative to the mean value 
of the control group (4 mice/group). Data are reported as mean ± SEM. 
Pharmacokinetics 
Nude mice subcutaneously xenografted with MV4-11 cells received gilteritinib 
suspended in a 0.5% methylcellulose solution as an oral single dose. Blood samples were 
collected at protocol-specified time points from the inferior vena cava using a syringe 
with EDTA-2Na, and plasma samples were prepared by centrifugation (n=3 per group; 
five plasma samples showed abnormal results and were not used for data analysis). 
Tumor samples were also collected from each mouse and tumor weight was measured. 
The plasma and tumor concentrations of gilteritinib were measured using high-
performance liquid chromatography-tandem mass spectrometry at Nemoto Science 
(Ibaraki, Japan). Standard pharmacokinetic parameters (Cmax, Tmax, and AUCt) were 
calculated from the mean concentrations of gilteritinib using WinNonlin V6.1 (Certara, 
Princeton, NJ). 
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Intra-bone marrow transplantation model 
In the intra-bone marrow transplantation (IBMT) model, MV4-11-luc cells (1×106 
cells/mouse) were injected into the bone marrow of the left tibia of female NOD-SCID 
mice (day 0) following the protocol detailed by Lee et al (73). Tumor growth was 
monitored by bioluminescent imaging of the whole body with an IVIS Spectrum 
(PerkinElmer, Waltham, MA). After confirming tumor cell engraftment at day 14, mice 
were orally administered with once-daily vehicle control or gilteritinib at 30 mg/kg from 
day 15 to day 70 (n=10). Tumor growth was monitored once a week during the dosing 
period and then every other week until day 100. Survival was also monitored daily until 
day 168. 
Computational modeling 
Docking simulation of gilteritinib with FLT3 was performed using the docking 
software GLIDE implemented in Maestro version 9.7 (Schrodinger, LLC, New York, 
NY). The coordinate of ligand–protein binding for FLT3 was modeled based on the ATP-
binding form of cKIT, which had the most similar kinase domain amino acid sequence 
in the Protein Data Bank (PDB) (PDB ID: 1PKG, chain A) and, therefore, was used as a 
surrogate for FLT3. The homology modeling was done by the modeling software MOE 
(Chemical Computing Group Inc., Montreal, Quebec, Canada). Hydrogen atoms were 
added using the computer program Protonate3D implemented in MOE. The docking 
mode with the highest docking score was employed. All molecular visualization was 
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produced by MOE. 
Statistical analyses 
For the in vivo subcutaneous xenograft mouse model, values are expressed as mean ± 
SEM. Tumor volume and body weight on day 28 in the gilteritinib-treated groups were 
compared with those in the control group using Dunnett’s test. For the IBMT model, the 
bioluminescence value on day 42 from the gilteritinib-treated group was compared with 
that from the control group using Student’s t-test. The median survival times were 
compared using the log-rank test. P<0.05 was considered significant. SAS software 
(SAS Institute Inc., Cary, NC), Microsoft Excel (Microsoft, Redmond, WA), and 
GraphPad Prism (GraphPad Software, La Jolla, CA) were used for data processing. 
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Results 
Gilteritinib inhibitory activity 
Gilteritinib (structure provided in Fig. 10A) inhibited the activity of eight of the 78 
tested kinases by over 50% at concentrations of either 1 nM (FLT3, LTK, ALK, and 
AXL) or 5 nM (TRKA, ROS, RET, and MER) (Table 6). The IC50 values were 0.29 nM 
for FLT3 and 0.73 nM for AXL. Gilteritinib inhibited FLT3 at an IC50 value that was 
approximately 800-fold more potent than the concentration required to inhibit c-KIT 
(230 nM; Table 7).  
My colleagues and I next evaluated the antiproliferative activity of gilteritinib against 
MV4-11 and MOLM-13 cells, which endogenously express FLT3-ITD. After 5 days of 
treatment, gilteritinib inhibited the growth of MV4-11 and MOLM-13 cells with mean 
IC50 values of 0.92 nM (95% CI: 0.23–3.6 nM) and 2.9 nM (95% CI: 1.4–5.8 nM), 
respectively (Fig. 10B). Growth suppression of MV4-11 cells was accompanied by 
inhibition of FLT3 phosphorylation. Relative to vehicle control cells, phosphorylated 
FLT3 levels were 57%, 8%, and 1% after 2 h of treatment with 0.1 nM, 1 nM, and 10 
nM gilteritinib, respectively (Fig. 10C). In addition, doses as low as 0.1 nM or 1 nM 
resulted in the suppression of phosphorylated ERK, STAT5, and AKT, all of which are 
downstream targets of FLT3 activation (Fig. 10D, Table 8). To investigate AXL-
inhibitory activity in cells, MV4-11-AXL cells with exogenous AXL expression were 
treated with gilteritinib. Gilteritnib at 1 nM, 10 nM, and 100 nM for 4 h treatment 
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decreased the phosphorylated AXL levels to 38%, 29%, and 22%, respectively (Fig. 11). 
Pharmacokinetic profile and pharmacodynamic effects of gilteritinib in an MV4-11 
xenograft mouse model  
The maximal plasma concentrations of gilteritinib were observed 2 h after a single 
oral administration of gilteritinib at 1 mg/kg, 6 mg/kg, and 10 mg/kg to MV4-11 
xenografted mice. By contrast, the maximal intratumor concentrations were observed 4 
h (1 mg/kg) or 8 h (6 mg/kg and 10 mg/kg) after dosing. Cmax and AUCt in plasma and 
tumors increased with increasing doses between 1 mg/kg and 10 mg/kg. The 
concentration in tumors was higher than that in plasma at each time point (Fig. 12A, B, 
Table 9). 
Phosphorylated FLT3 decreased by approximately 40% compared with control 
phosphorylation levels in tumor samples within 1 h after single oral administration of 1–
10 mg/kg gilteritinib (Fig. 12C), indicating target inhibition by gilteritinib. Although the 
decreased phosphorylation state observed in the 1 mg/kg treatment group had returned 
to the pre-treatment level by 24 h, the marked decrease in phospho-FLT3 seen with 10 
mg/kg was maintained throughout the 24 h experimental period. Furthermore, the 
phosphorylation level of STAT5, a downstream target of FLT3, was almost completely 
abolished in tumors 4 h and 8 h after single administration of gilteritinib at doses of either 
6 mg/kg or 10 mg/kg, respectively. STAT5 phosphorylation levels remained low 24 h 
post drug, approaching only 20% of baseline levels (Fig. 12D). A dose of 3 mg/kg 
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gilteritinib also decreased phospho-STAT5 to <20% of baseline levels at 4 h and 8 h, but 
returned to approximately 50% by 24 h. 
The effect on tumor burden of inhibiting FLT3 phosphorylation was assessed 
following 28 days of once-daily oral administration of gilteritinib. Significant growth 
inhibition of MV4-11 tumors was observed at 1 mg/kg/day (63% inhibition; P<0.05) and 
3 mg/kg/day (80% inhibition; P<0.01), and near-complete tumor regression was seen at 
6 mg/kg/day (93%; P<0.001) and 10 mg/kg/day (100%; P<0.001) (Fig. 12E). Four of 
the six mice in the 6 mg/kg/day group experienced complete tumor regression; all six 
mice in the 10 mg/kg/day group experienced complete tumor regression. Body weight 
was not affected by treatment with gilteritinib at any tested dose (Fig. 12F). 
Inhibitory activity of gilteritinib against FLT3 containing ITD ± D835Y or F691L/I 
mutations 
Since mutations within the TKD of FLT3 (eg, FLT3-D835Y or FLT3-F691) often 
confer resistance to FLT3 inhibitors that were previously effective against FLT3-ITD 
(74), the effect of gilteritinib on these resistance mutations was studied. Gilteritinib 
inhibited the cell growth of Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, 
FLT3-ITD-D835Y, FLT3-ITD-F691L, or FLT3-ITD-F691I, with IC50 values of 1.8 nM 
(95% CI: 1.0–3.0 nM), 1.6 nM (95% CI: 1.1–2.4 nM), 2.1 nM (95% CI: 1.4–3.0 nM), 22 
nM (95% CI: 15–33 nM), and 49 nM (95% CI: 29–83 nM), respectively (Table 10). The 
growth of parental Ba/F3 cells in the presence of IL-3 was inhibited with an IC50 value 
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of 420 nM (95% CI: 350–500 nM), which represents the off-target inhibition of kinases 
other than FLT3. My colleagues and I confirmed that phosphorylation of FLT3 and its 
downstream targets STAT5, AKT, and ERK were inhibited by gilteritinib in a dose-
dependent manner in Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, or FLT3-
ITD-D835Y (Fig. 13). Furthermore, in nude mice xenografted with Ba/F3 cells 
expressing either FLT3-ITD, FLT3-D835Y, or FLT3-ITD-D835Y, gilteritinib showed 
antitumor efficacy at 10 mg/kg and 30 mg/kg, and induced tumor regression at 30 mg/kg, 
in all three models (Fig. 14). As for quizartinib, 2nd generation FLT3 inhibitor, the IC50 
values of growth inhibition for Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, 
or FLT3-ITD-D835Y were 0.46 nM (95% CI: 0.078–2.8 nM), 5.7 nM (95% CI: 1.5–21 
nM), and 35 nM (95% CI: 9.3–130 nM), respectively. 
Gilteritinib binds to FLT3 at the ATP-binding site 
The finding that gilteritinib inhibited FLT3-D835Y and FLT3-ITD-D835Y, both of 
which harbor mutations in the activation loop essential for binding type 2 inhibitors, 
suggests that gilteritinib is a type 1 FLT3 inhibitor. To further understand the inhibitory 
activity of gilteritinib against mutated FLT3 at the structural level, computational 
modeling was performed for FLT3 with gilteritinib (Fig. 15). The modeling revealed that 
gilteritinib fits into the active (DFG [Asp-Phe-Gly]-in) conformation of FLT3 at the ATP-
binding site, far from the D835 position in the activation loop. The modeling also showed 
that gilteritinib hydrophobically interacts with FLT3 at the F691 position.  
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Gilteritinib prolongs survival in mice with IBMT of AML cells 
Treatment with gilteritinib showed a significant reduction in overall bioluminescence, 
with MV4-11-luc tumor growth dramatically reduced during the first 2 weeks of 
treatment (Fig. 16A), resulting in bioluminescence levels that were similar to that of 
background (around 106 photons/s) on the penultimate day of treatment (day 70). 
Furthermore, when control mice showed MV4-11 cell infiltration in several areas of the 
body, gilteritinib-treated mice had no evidence of cell infiltration (Fig. 16B). Gilteritinib 
treatment significantly increased survival of MV4-11 xenografted mice and all treated 
mice survived to day 168, whereas vehicle control mice had a median survival time of 
61.5 days (P<0.001) (Fig. 16C). 
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Discussion 
These data demonstrate that gilteritinib, a FLT3/AXL TKI, shows potent efficacy in 
preclinical models of FLT3-mutated AML. In vitro kinase assays using gilteritinib 
revealed strong inhibition of FLT3 and AXL (in the nM range) and an 800-fold weaker 
inhibition of c-KIT than FLT3. Gilteritinib also inhibited phosphorylation of FLT3 with 
ITD and/or activation loop D835Y mutations in cellular assays. The inhibitory activity 
of gilteritinib against the D835Y mutation is further supported by computational 
modeling that showed gilteritinib binds to FLT3 within the activation loop far from the 
D835 site, allowing kinase inhibition to occur in the face of FLT3 mutations at this 
location. This potent FLT3 inhibition translated to a marked decrease in the cell viability 
of FLT3 mutation-positive cell lines with inhibition of several downstream targets. In 
vivo, gilteritinib was distributed at high levels in tumors after single oral administration 
and showed antitumor activity against FLT3-driven tumors in a mouse xenograft model. 
This antitumor activity was associated with a durable inhibition of phospho-FLT3 and 
phospho-STAT5, demonstrating the in vivo inhibitory effect of gilteritinib. Furthermore, 
treatment with gilteritinib decreased the leukemic burden and prolonged survival in a 
mouse IBMT model. Taken together, these data suggest that gilteritinib blocks FLT3 
phosphorylation, impairs downstream signal transduction, and consequently inhibits 
AML cell proliferation in both in vitro and in vivo models. 
These preclinical findings regarding the activity of gilteritinib suggest it may be a 
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potential therapeutic treatment option for patients with FLT3-mutated AML. Although 
several TKIs have been investigated as potential therapies for AML, none have yet to be 
approved for clinical use (55, 62). First-generation FLT3 inhibitors, such as sunitinib and 
sorafenib, are pan-kinase inhibitors that non-selectively target FLT3; this non-specificity 
often leads to off-target kinase inhibition and severe toxicity in patients (55). Next-
generation inhibitors, such as gilteritinib, crenolanib, and quizartinib, more selectively 
target FLT3, suggesting less off-target effects and potentially decreased toxicity in 
patients. The data presented herein suggest that gilteritinib has a potent inhibitory effect 
on FLT3 with minimal impact on c-KIT, demonstrating the specificity of the compound. 
Studies have shown that mice deficient in both flt3 and c-kit show a large overall decrease 
in hematopoietic cell number, whereas mice deficient in only flt3 have normal mature 
hematopoietic populations with specific deficiencies in primitive B lymphoid 
progenitors (75). Thus, the targeted FLT3 inhibition and markedly weaker c-KIT 
inhibition by gilteritinib suggests a lower clinical risk of myelosuppression than often 
occurs with other TKIs (76).  
When comparing the next-generation FLT3 inhibitors in development, all three 
compounds exhibit similar activity against FLT3-ITD in vitro, inhibiting the growth of 
MV4-11 cells at low nM concentrations (gilteritinib: 0.92 nM, crenolanib: 1.3 nM, 
quizartinib: 0.56 nM) (77, 78). However, gilteritinib also showed potent inhibition of 
FLT3-D835Y and FLT3-ITD/D835Y mutations whereas quizartinib was ineffective at 
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blocking these mutations (79). My colleagues and I also confirmed the weaker activity 
of quizartinib against FLT3-D835Y and FLT3-ITD/D835Y mutations compared to 
FLT3-ITD. Thus, in contrast to quizartinib, gilteritinib has the advantage of effectively 
blocking FLT3-ITD/D835Y and FLT3-D835Y. These preclinical data suggest that 
gilteritinib may provide improved clinical efficacy even in the presence of the D835Y, a 
mutation that has been clinically shown to confer resistance to FLT3 inhibitor treatment 
(80). In addition, in cellular assays, gilteritinib showed inhibitory activity against F691 
mutations, a mutation also detected in patients with AML who have relapsed following 
quizartinib treatment (79, 81). However, in those assays, inhibition of cell viability for 
cells expressing FLT3-F691 was 10-fold to 20-fold weaker than for cells expressing 
FLT3-ITD, suggesting potential efficacy depending on the exposure level achieved in 
patients.  
Although several similarities exist between gilteritinib and crenolanib (eg, effective 
inhibition of FLT3-D835Y and high selectivity for FLT3 compared with c-KIT), 
crenolanib treatment showed limited efficacy at the maximum tolerated dose in a 
xenograft mouse model in which MV4-11-luc cells were inoculated by intravenous 
injection, resulting in a significant survival benefit without a complete reduction in tumor 
cells (77). By contrast, 30 mg/kg gilteritinib induced a significant reduction in 
bioluminescence from tumor cells to levels near background bioluminescence and 
improved survival such that all mice in the gilteritinib-treatment group remained alive 
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during the experimental period. Furthermore, 30 mg/kg gilteritinib treatment continued 
to suppress the bioluminescence around 3 months post treatment, suggesting that this 
dose is also effective against minimum residual disease in bone marrow in this model. 
Overall, the cellular and animal model data suggest that gilteritinib may be advantageous 
compared with the other FLT3 inhibitors in development because it effectively blocks 
mutated FLT3 (both FLT3-ITD and FLT3-D835Y). 
In addition to the strong preclinical inhibition of FLT3, gilteritinib also targets AXL. 
In vitro studies have shown that AXL is important for both wild-type and mutant FLT3 
activation, suggesting that AXL may have a role in the pathobiology of AML (70). 
Furthermore, preclinical evidence in FLT3-ITD expressing cells suggests that activation 
of AXL may be required for the development of acquired resistance to FLT3 inhibitors 
(72). Additional in vivo studies have demonstrated that blocking AXL can suppress the 
growth of FLT3-ITD AML (70), decrease tumor size (69), and block the activation of 
cellular survival pathways while upregulating the apoptotic pathway (69). Thus, the 
preliminary preclinical data presented herein, showing that gilteritinib inhibits AXL at 
concentrations similar to that for FLT3, suggest that dual inhibition of this pathway may 
lead to improved efficacy in the treatment of AML; however, it remains unclear whether 
AXL inhibition played a role in the tumor regression and improved survival induced by 
gilteritinib in the IBMT model. 
Although these preclinical studies clearly demonstrate the potent activity of 
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gilteritinib on FLT3 coupled with minimal activity against c-KIT, a few limitations 
should be noted. While these data are suggestive of a possible enhanced benefit to 
blocking both FLT3 and AXL, further studies are needed to fully characterize and 
understand the effect of gilteritinib on AXL in preclinical models thereby helping to fully 
elucidate the role of AXL in FLT3-mutated AML. In addition, understanding the effect 
of gilteritinib in cells from patients with AML may help shed light on the clinical 
implications of treatment with a FLT3-mutant inhibitor because the patient’s cells will 
be heterogeneous for the FLT3 mutation.  
Overall, gilteritinib showed consistently potent inhibition of FLT3 in preclinical 
studies and demonstrated strong efficacy in FLT3-mutant tumor models. Furthermore, 
initial in vitro assays suggest that gilteritinib effectively blocks AXL activity while 
having minimal effect on c-KIT. Based on these data, it can be postulated that gilteritinib 
may lead to a reduced blast number and prolonged survival in patients with FLT3-ITD- 
or FLT3-D835Y-positive AML. This hypothesis requires confirmation in clinical studies. 
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Tables 
 
Table 6. Inhibitory activity of gilteritinib against various tyrosine kinases 
 
Inhibitory assay for the panel of tyrosine kinases was conducted using off-chip MSA. 
Percentage inhibitions were determined in a single experiment 
  
1 nM 5 nM 1 nM 5 nM
ABL -13.1 -10.4 HCK -8.1 -6.6
ACK -4.1 -2.5 HER2 -7.9 -8.9
ALK 76.1 97.6 HER4 -1.0 -6.1
ARG -4.0 -3.7 IGF1R 6.4 24.1
AXL 54.3 85.5 INSR 10.5 37.3
BLK -3.6 -1.0 IRR 7.2 23.4
BMX -5.0 -4.1 ITK -0.6 0.6
BRK -10.0 -0.7 JAK1 -8.1 -5.5
BTK -3.0 6.1 JAK2 -1.7 6.3
CSK 1.2 -3.1 JAK3 -0.7 7.4
DDR1 1.4 14.0 KDR -1.6 3.1
DDR2 2.4 13.3 KIT 0.5 0.5
EGFR 0.8 1.0 LCK -5.2 2.3
EPHA1 4.8 17.6 LTK 81.8 97.5
EPHA2 -6.9 -8.7 LYNa -3.8 -1.4
EPHA3 -8.6 -7.4 LYNb -3.5 -1.3
EPHA4 -6.4 -3.4 MER 21.5 55.7
EPHA5 -5.1 -8.8 MET -0.5 5.0
EPHA6 -11.0 -9.5 MUSK -4.9 8.5
EPHA7 -7.3 -12.0 PDGFRα -5.4 13.0
EPHA8 -5.2 -10.3 PDGFRβ -3.8 2.4
EPHB1 -7.1 -4.8 PYK2 -0.4 2.1
EPHB2 -6.1 -7.8 RET 26.0 65.5
EPHB3 -6.6 -10.0 RON 0.4 6.8
EPHB4 -6.0 -9.1 ROS 35.0 71.7
FAK -5.6 -8.3 SRC -2.1 1.6
FER 5.2 21.7 SRM -7.3 -8.6
FES -0.2 -0.8 SYK -9.3 6.1
FGFR1 -5.6 -6.0 TEC -2.2 -4.5
FGFR2 -7.0 -6.6 TIE2 -9.4 -13.5
FGFR3 -9.5 -6.9 TNK1 -1.0 5.1
FGFR4 -9.2 -7.7 TRKA 38.3 74.9
FGR -2.3 6.0 TRKB 6.6 23.8
FLT1 -2.1 3.9 TRKC 4.7 29.9
FLT3 86.8 96.4 TXK -2.6 -1.1
FLT4 -4.3 25.7 TYK2 -5.7 -4.5
FMS 2.1 20.0 TYRO3 -7.8 2.0
FRK -5.1 1.1 YES 1.3 12.9
FYN 3.8 4.8 ZAP70 -5.6 -7.8
% inhibition
Kinase Kinase
% inhibition
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Table 7. Inhibitory activity of gilteritinib against various tyrosine kinases. 
 
Inhibitory assay for the indicated tyrosine kinases (TK) was conducted using a TK-
ELISA or Off-chip MSA. IC50 values were determined for TKs that were inhibited by 
more than 50% at 5 nmol/L in1 or 3 (for FLT3 and c-KIT) individual experiments. 
  
Kinase IC50 (nmol/L)
FLT3 0.29
LTK 0.25
ALK 0.42
AXL 0.70
c-KIT 230
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Table 8. Gilteritinib inhibition of phosphorylated STAT5, AKT, and ERK in MV4-11 
cells 
Target 
Kinase inhibition at the specified gilteritinib concentration (%) 
0.1 nM 1 nM 10 nM 
p-STAT5 114 23 0 
p-AKT 65 48 9 
p-ERK 54 22 1 
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Table 9. Pharmacokinetic parameters of gilteritinib after single oral dosing of 
gilteritinib in nude mice xenografted with MV4-11 cells  
Plasma concentration 
Dose (mg/kg) Cmax (ng/mL) AUCt (ng∙h/mL) 
1 6.558 25.20 
6 45.90 269.0 
10 83.01 492.8 
Intratumor concentration 
Dose (mg/kg) Cmax (ng/g) AUCt (ng∙h/g) 
1 90.61 1186 
6 772.1 12880 
10 1125 17330 
AUCt, area under the plasma concentration–time curve from time 0 h to the last 
determinable time point;  
Cmax, maximum plasma concentration. 
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Table 10. Antiproliferative activity of gilteritinib against Ba/F3 cells expressing either 
FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691L or FLT3-ITD-F691I 
Test 
compound 
IC50 (nmol/L) 
ITD D835Y 
ITD 
-D835Y 
ITD 
-F691L 
ITD 
-F691I 
Ba/F3 
IL3 (+) 
Gilteritinib 1.8 1.6 2.1 22 49 420 
The IC50 values of each experiment were calculated via Sigmoid-Emax model non-linear 
regression analysis. The geometric means from 3 individual experiments are shown.  
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Figures 
 
Fig. 10. Gilteritinib inhibits cell growth in AML cells and blocks phosphorylation of 
FLT3 and its downstream targets  
(A) Structure of gilteritinib (ASP2215). (B) MV4-11 and MOLM-13 cells were treated 
with DMSO or increasing concentrations of gilteritinib for 5 days, and cell viability was 
measured using CellTiter-Glo. A representative result from three independent 
experiments is shown. Data are presented as mean ± SEM (quadruplicate). (C) 
Immunoprecipitation and immunoblot for phosphorylated FLT3 and total FLT3 in MV4-
11 cells treated with DMSO or increasing concentrations of gilteritinib for 2 h. Blots 
from one study, which was done in triplicate, are shown. Densitometry values are listed 
below each treatment group. (D) Immunoblot for phosphorylated AKT, ERK, and STAT5 
in gilteritinib-treated MV4-11 cells. Blots from one study, which was done in triplicate, 
are shown. 
 86 
 
 
  
(A)
(B)
N
H
N
H3CO
N
N
H3C
N
N
CH3
N
H
OO
NH2
(C)
(D)
p-F
F
Gilte
(n
Log [Gilteritinib] (mol/L)
C
el
l p
ro
li
fe
ra
ti
on
(%
 o
f c
on
tr
ol
)
-11 -10 -9 -8 -7
0
20
40
60
80
100
120
MV4-11
MOLM13
 87 
 
Fig. 11. Gilteritinib inhibits phosphorylation of AXL in MV4-11-AXL cells.  
MV4-11-AXL cells exogenously expressing AXL were cultured overnight and treated 
with a dose course of gilteritinib for 4 h. Protein lysates were collected in RIPA buffer 
and immunoblotting was performed to detect both the phosphorylated and total form 
of AXL. Densitometry was performed to determine the percentage inhibition of the 
phosphorylated form of AXL in relation to the total protein compared with the vehicle 
control group. Data are presented as mean percentage inhibition; results are shown 
(triplicate). 
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Fig. 12. Antitumor activity of gilteritinib in an MV4-11 xenograft AML mouse model 
(A) Plasma concentrations of gilteritinib were determined by high-performance liquid 
chromatography-tandem mass spectrometry from nude mice subcutaneously 
xenografted with MV4-11 cells and treated with a single oral dose of gilteritinib. Data 
are presented as mean ± SD for two or three animals. (B) Tumor concentrations of 
gilteritinib were determined by high-performance liquid chromatography-tandem mass 
spectrometry from nude mice subcutaneously xenografted with MV4-11 cells and treated 
with a single dose of gilteritinib. Data are presented as mean ± SD for three animals. 
Symbols represent treatment groups: 1 mg/kg (●), 6 mg/kg (▲), 10 mg/kg (■). (C and 
D) Male mice xenografted with MV4-11 cells were orally treated with either vehicle 
control or increasing concentrations of gilteritinib. Protein lysates were collected over a 
24 h time course for assessment of (C) phospho-FLT3 to total FLT3 as determined by 
ELISA or (D) phospho-STAT5 and total STAT5 as determined by immunoblot. Data are 
presented as the ratio of phosphorylated protein levels normalized to total protein levels 
relative to vehicle control-treated lysates. (E and F) Male mice xenografted with MV4-
11 cells were orally treated with either vehicle control or increasing concentrations of 
gilteritinib over a 28-day period to examine the effect of drug on (E) tumor volume and 
(F) body weight. Data presented as mean ± SEM for n=6 mice/group. Symbols represent 
treatment groups: 1 mg/kg (●), 3 mg/kg (▼), 6 mg/kg (▲), 10 mg/kg (■). *P<0.05, 
**P<0.01, and ***P<0.001 compared with the value of the control group on Day 28 
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(Dunnett’s test).  
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Fig. 13. Gilteritinib potently inhibits FLT3 and its downstream targets in Ba/F3 cells 
expressing mutant FLT3  
Ba/F3 cells expressing mutant forms of FLT3 were cultured overnight and treated with 
a dose course of gilteritinib for 2 h. Protein lysates were collected in RIPA buffer and 
immunoblotting was performed to detect both the phosphorylated and total form of the 
target proteins FLT3, STAT5, AKT, and ERK. Immunoblot results from (A) Ba/F3 cells 
expressing FLT3-ITD, (B) Ba/F3 cells expressing FLT3-D835Y, (C) Ba/F3 cells 
expressing FLT3-ITD-D835Y. Densitometry was performed to determine the percentage 
inhibition of the phosphorylated form of each target in relation to the total protein 
compared with the vehicle control group. Data are presented as mean percentage 
inhibition; results are shown (triplicate) 
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Fig. 14. Gilteritinib potently inhibits FLT3 mutant-expressing tumors in a mouse 
xenograft model  
Male nude mice were xenografted with Ba/F3 cells expressing FLT3-ITD, FLT3-D835Y, 
or FLT3-ITD-D835Y. Following confirmed tumor growth, mice were treated with either 
10 mg/kg or 30 mg/kg once-daily oral gilteritinib for up to 7 days. Tumor volume was 
assessed at specified time points in (A) FLT3-ITD xenografted mice, (B) FLT3-D835Y 
xenografted mice, and (C) FLT3-ITD-D835Y xenografted mice. Data presented are 
mean ± SEM for n=5 mice/group. Symbols represent treatment groups: control (○), 10 
mg/kg (■), and 30 mg/kg (♦). **P<0.01 and ***P<0.001 compared with the value of the 
control group on Day 7 (Dunnett’s test). 
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Fig. 15. Computational modeling of gilteritinib binding to wild-type FLT3  
Gilteritinib is shown as a ball-and-stick model. All of atoms are colored by the type of 
element (white: hydrogen; cyan and gray: carbon; blue: nitrogen; red: oxygen). The 
protein surface is colored by electrostatic potential (blue: positive; red: negative; white: 
neutral). For clarity, the hydrogen atoms of the protein are omitted with the exception of 
the polar hydrogen atoms of the side-chains of K614 and K644; similarly, the protein 
surface in front of the gatekeeper residue F691 is hidden. 
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Fig. 16. Gilteritinib significantly decreases leukemic burden and increases survival in an 
intra-bone marrow transplantation model of AML 
Female NOD-SCID mice engrafted with MV4-11-luc cells were treated once daily with 
vehicle (■) or 30 mg/kg gilteritinib (●) for 56 days beginning on day 15. Bar represents 
treatment period. (A) MV4-11-luc cell bone marrow infiltration was monitored using 
whole-body imaging. Data presented as mean ± SEM for n=10 mice/group. ***P<0.001 
compared with the value of the control group on day 42 (Student’s t-test). (B) 
Representative whole-body bioluminescence images from day 21 and day 42 are shown. 
(C) Kaplan–Meier analysis curve of mouse survival. ***P<0.001 compared with the 
value of the control group (Log-rank test). 
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General Discussion 
Gene mutation and genomic abnormality are the characteristics of cancer leading to 
aberrant cell growth (2-4). These alterations are the initial step for cancer development. 
Tumors accumulate abnormalities during their somatic evolution of life and acquire 
intra-tumor heterogeneity (7). When malignant cells obtain a driver mutation or genetic 
alteration on oncogene or tumor suppressor gene, their feature becomes more aggressive 
and dominant in tumor tissues. In the studies described here in this dissertation, I 
investigated the driver mutation dependencies of the target tumor cells harboring EML4-
ALK or FLT3 with constitutively active mutation using each inhibitor, ASP3026 or 
gilteritinib. I also examined the basic profile of each inhibitor as an antitumor drug. 
ASP3026 ALK inhibitor showed growth inhibitory activity in ALK-fusion positive 
NSCLC models supporting the ALK dependency of EML4-ALK positive tumor cells as 
assessed by previous publications (24). FLT3 dependency of FLT mutated cells was also 
shown in the inhibitory studies of gilteritinib in AML cells and model animals. In the 
report with clenoranib (82), a FLT3 inhibitor, it inhibited the cell growth of MV4-11 and 
MOLM14 cells with the similar potency. However, the inhibitory activities of both 
compounds were different among cells and/or models tested. For example, ASP3026 at 
3 mg/kg induced tumor regression in mice xenografted with NCI-H2228 cells, but 
ASP3026 at 10 mg/kg did not induce tumor regression in the hEML4-ALK transgenic 
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mouse model although it induced regression at 30 mg/kg. The IC50 values of gilteritinib 
were 0.92 nM for the growth of MV4-11 cells, which have ITD mutation in both alleles, 
and 2.9 nM for that of MOLM-13 cells, which alleles consist of mutated and wild type 
FLT3. These findings suggest the difference in the extent of dependency in tumor cells 
upon each driver mutation.  
Cancer dynamically evolves in its biological properties even with the treatment, and 
consequently acquires resistant potencies to the therapy which is often observed as 
appearance of treatment-resistant mutation of target molecules and/or activation of 
another kinase which can activate the downstream of the original target kinase (83). The 
ALK inhibitor crizotinib showed high efficacy in clinical trials with NSCLC patients 
harboring EML4-ALK, but the treatment was not curative, and the patients developed 
resistance to crizotinib with a progression free survival of only approximately 10 months 
(16-18). The gatekeeper-residue mutation L1196M of ALK was initially found in the 
relapsed patients (39, 46-48). In my studies, crizotinib showed no efficacy for the 
L1196M mutation in a xenograft model at the clinically achievable dose level. On the 
other hand, ASP3026 induced tumor regression in the model as well as a wild-type 
EML4-ALK model. In a first-in-human, open-label dose-escalation and dose-expansion 
study of ASP3026, its safety, pharmacokinetics, and antitumor effects were evaluated in 
patients with advanced solid tumors (84). Among 16 crizotinib-resistant patients with 
ALK positive tumors evaluated, 8 patients achieved partial response. The mean plasma 
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ASP3026 concentration was around 300 ng/mL (500 nM) at a steady state of 325 mg/day, 
the maximum tolerated dose, which was considered high enough to show the antitumor 
efficacy considering the nonclinical data. ASP3026 could achieve the relatively higher 
exposure on ALK inhibition to the extent that it inhibits the ‘gate keeper’ mutation with 
a tolerable safety profile compared to crizotinib in patients. This is thought to be one 
major reason for ASP3026 to show the efficacy against crizotinib-resistant tumors. 
However, the outcomes were tentative and not curative. The disease progressed over 
time in spite of continued treatment potentially due to tumor cells’ evolution to a 
treatment-resistant form in a whole organization. 
ASP3026 induced rapid tumor regression in subcutaneous, intrapleural, and intra-
hepatic NCI-H2228 xenograft and transgenic mouse models, but the tumors were not 
disappeared at the end of each treatment period. In tumors, ALK fusion positive NSCLC 
cells were considered to survive. In comparison with the data using ASP3026, there was 
one clear difference observed with gilteritinib that AML cells were disappeared by the 
treatment in in vitro and in vivo settings. The difference in outcomes between NSCLC 
cells treated with ASP3026 and AML cells treated with gilteritinib might be related to 
the fact AML has the lowest number of mutations among cancers (85). Although AML 
is not a single-gene mutated disease, its complexity of mutation is lower than solid 
tumors and AML tends to be sensitive to the chemo-therapies. In the clinical trial of 
gilteritinib in relapsed or refractory AML patients, 70 (37%) achieved composite 
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complete remission out of 191 FLT3 mutation-positive patients (86). On the other hand, 
five (9%) of 58 FLT3 wild type AML patients achieved composite complete remission. 
However, the outcomes seemed to be tentative and not curative also in these AML cases 
with gilteritinib in the preliminary analysis reported (87). Analysis of gilteritinib resistant 
clones revealed the acquisition of new driver mutations and selection for FLT3 wild type 
AML cells. My studies indicated gilteritinib had a potency to eradicate FLT3-ITD 
positive AML cells if efficiently exposed. Again, AML is also known to be a 
heterogeneous disease even in the same patient (85, 88). FLT3-ITD mutation is thought 
to happen in the late events of leukemogenesis. Consequently, when the blasts from FLT3 
mutation-positive AML patients were analyzed for the FLT3 in a single cell polymerase 
chain reaction, multiple clones consisting of FLT3 wild type, FLT3-ITD/wild type, and 
homogeneous FLT3 ITD positive blasts were detected in the same patient. Once FLT3 is 
mutated to gain ITD after initiation of leukemogenesis, the blast becomes more 
aggressive and dominant. The malignant extent further progresses if both alleles gain the 
ITD mutation through loss of heterozygosity. Gilteritinib is thought to effectively reduce 
the number of FLT3 ITD positive blasts. But, it did not happen in all patients, and 
resistant clones with less FLT3 dependency appear over time as a consequence of cancer 
evolution with the treatment. 
There are other possibilities for causes of resistance than appearance of treatment-
resistant mutation of the target molecule and/or activation of another kinase which can 
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activate the downstream of the original target kinase (83). Recently, immuno-oncology 
agents, e.g. anti-programmed cell death 1 (PD1) antibody and anti-cytotoxic T 
lymphocyte antigen-4 (CTLA4) antibody, have shown attractive outcomes in solid tumor 
patients (89-91). The drugs induced complete tumor regression and the efficacies lasted 
for a long period in a subset of patients. Tumor cells acquire the ability to escape from 
immune surveillance through several ways including upregulation of immune 
checkpoint molecules (92). It has been proven the modification of cancer 
microenvironment makes tumor cells to be sensitive to immune cells at least in highly 
immune cell infiltrated or 'hot' tumors. The combination of ASP3026 or gilteritinib with 
these types of immune check point inhibitors might further improve the outcome of 
patients. Anyway, it is highly important to conduct real-time monitoring of tumors 
including microenvironment through repeated biopsies so that one can understand the 
current tumor biology and find appropriate treatments for the patients.  
Overall, my studies revealed the basic profiles of ASP3026 and gilteritinb as 
molecular target therapy candidates for cancer patients, and also indicated the different 
dependency among tumor cells on each driver mutation with the outcomes of clinical 
trials. These compounds would be useful for further understanding the dramatic 
evolution of cancer. 
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